WO1996040250A2 - Immunoglobuline chimerique specifique des plaquettes et procedes d'utilisation - Google Patents

Immunoglobuline chimerique specifique des plaquettes et procedes d'utilisation Download PDF

Info

Publication number
WO1996040250A2
WO1996040250A2 PCT/US1996/010216 US9610216W WO9640250A2 WO 1996040250 A2 WO1996040250 A2 WO 1996040250A2 US 9610216 W US9610216 W US 9610216W WO 9640250 A2 WO9640250 A2 WO 9640250A2
Authority
WO
WIPO (PCT)
Prior art keywords
fab
immunoglobulin
iiia
patients
antibody
Prior art date
Application number
PCT/US1996/010216
Other languages
English (en)
Other versions
WO1996040250A3 (fr
Inventor
Barry S. Coller
David M. Knight
Original Assignee
Centocor, Inc.
The Research Foundation Of State University Of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor, Inc., The Research Foundation Of State University Of New York filed Critical Centocor, Inc.
Priority to AU63323/96A priority Critical patent/AU6332396A/en
Priority to JP9502244A priority patent/JPH11511120A/ja
Priority to EP96922452A priority patent/EP0835135A2/fr
Publication of WO1996040250A2 publication Critical patent/WO1996040250A2/fr
Publication of WO1996040250A3 publication Critical patent/WO1996040250A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Definitions

  • Platelet aggregation is an essential event in the formation of blood clots. Under normal circumstances, blood clots serve to prevent the escape of blood cells from the vascular system. However, during certain disease states, clots can restrict or totally occlude blood flow resulting in cellular necrosis. For example, platelet aggregation and subseguent thrombosis at the site of an atherosclerotic plague is an important causative factor in the genesis of conditions such as angina, acute myocardial infarction, and reocclusion following successful thrombolysis and angioplasty. Heart attack patients are typically treated with thrombolytic agents such as tissue plasminogen activator or streptokinase, which dissolve the fibrin component of clots.
  • thrombolytic agents such as tissue plasminogen activator or streptokinase
  • a major complication associated with fibrinolysis is reocclusion based on platelet aggregation which can result in further heart damage.
  • glycoprotein (GP)IIb/IIIa receptors are known to be responsible for platelet aggregation
  • reagents which block these receptors are expected to reduce or prevent reocclusion following thrombolytic therapy and to accelerate the rate of thrombolysis.
  • Such reagents are also expected to be useful in therapy of other vaso-occlusive and thromboembolic disorders.
  • a murine monoclonal antibody designated 7E3 that inhibits platelet aggregation and appears useful in the treatment of human thrombotic diseases is described in published European Patent Application Nos. 205,207 and 206,532. It is known in the art that murine antibodies have characteristics which may severely limit their use in human therapy. As foreign proteins, murine antibodies may elicit immune reactions that reduce or destroy their therapeutic efficacy and/or evoke allergic or hypersensitivity reactions in patients. The need for readministration of such therapeutic modalities in thromboembolic disorders increases the likelihood of these types of immune reactions.
  • Chimeric antibodies consisting of non-human binding regions joined to human constant regions have been suggested as a means to circumvent the immunoreactivity problems of murine antibodies. See Proc. Natl. Acad. Sci. USA. .81.6851 (1984) and PCT Application No. PCT/GB85 00392. Since the constant region is largely responsible for the immunoreactivity of some antibody molecules, chimeric antibodies with constant regions of human origin have been surmised to be less likely to evoke an anti-murine response in humans. However, it is unpredictable whether the joining of a human constant region to a murine binding region of a desired specificity will reduce immunoreactivity (e.g., the extent and/or incidence of immunogenicity) and/or alter the binding capability of the resulting chimeric antibody.
  • This invention pertains to a platelet-specific chimeric immunoglobulin comprising a variable or antigen binding region of non-human origin and a constant region of human origin.
  • the chimeric immunoglobulins can be specific for GPIIb/IIIa receptor or other platelet components.
  • These antibodies bind to platelets and can block platelet aggregation and thus are useful as antithrombotic agents, in the prevention or reduction of occlusion or reocclusion in a variety of clinical situations (e.g., following thrombolytic therapy, concomitant with angioplasty) , and in the prevention of stenosis and/or restenosis.
  • an agent which binds GPIIb/IIIa and the vitronectin receptor is used to reduce or prevent occlusion, reocclusion (e.g., abrupt closure), stenosis and/or restenosis.
  • the anti-platelet antibodies of the present invention are also useful in imaging.
  • Figure 1 is a schematic diagram of the results of a Northern analysis of heavy chain and light chain mRNAs for the 7E3 monoclonal antibody using cloned variable regions as probes.
  • Figures 2A-2B are schematic representations of the plasmids p7E3V x hC_ (Fig. 2A) and p7E3V H hC G4 (Fig. 2B) , which carry the chimeric gene constructs encoding the light and heavy chains, respectively, of a chimeric 7E3 immunoglobulin.
  • Figure 3 shows the binding of the chimeric 7E3 immunoglobulin encoded by vectors p7E3V ⁇ hC ⁇ and p7E3V H hC G4 to platelets.
  • Figure 4 shows the inhibition of platelet aggregation by a chimeric 7E3 (c7E3) immunoglobulin.
  • Figure 5 is a graph of the plasma antibody concentration (ng/mL) versus time (days) , which illustrates the rapid initial clearance of c7E3 Fab (7,, .) from the plasma in three patients with stable coronary disease, following a 0.20-mg/kg dose of c7E3 Fab administered intravenously as a five minute infusion.
  • Figures 6A-6C are illustrations summarizing the effect on platelet activity of a single bolus dose of chimeric 7E3 Fab (0.15 mg/kg, 0.20 mg/kg or 0.25 mg/kg) 2 hours after administration of antibody (7,, K ) .
  • a dose response is evident when platelet activity is assayed in terms of receptor blockade (Figure 6A) , platelet aggregation ( Figure 6B) , and bleeding time ( Figure 6C) .
  • the lines represent median values.
  • Figures 7A-7C are illustrations of the duration of anti-platelet effect of chimeric 7E3 Fab (7 1 , *.) administered prior to angioplasty in a bolus dose of 0.25 mg/kg.
  • the lines indicate the median values from time zero at baseline through 24 hours for receptor blockade (Figure 7A) , platelet aggregation ( Figure 7B) , and bleeding time ( Figure 7C) .
  • Figures 8A-8C are illustrations summarizing the anti-platelet activity of a 0.25 mg/kg bolus dose followed by a 12 hour continuous infusion (10 ⁇ g/minute) of chimeric 7E3 Fab (7,, K) in 11 patients.
  • the lines represent median values determined for percent receptor blockade (Figure 8A) , percent of pre-dose (baseline at time zero) platelet aggregation (Figure 8B) , and bleeding times (Figure 8C) .
  • Figure 9 is an illustration of the absolute change in hematocrit from baseline to a time 24 hours following the end of infusion for 47 patients described in Example 4.
  • Figure 10 is a Kaplan-Meier plot illustrating the probability of no urgent repeat percutaneous revascularization procedures from the time of randomization for the three treatment groups.
  • Figure 11 is a graph displaying the odds ratios and 95% confidence intervals for key subgroups (listed at right) entered in the trial. Data are presented for the primary efficacy endpoint (death, nonfatal infarction, urgent angioplasty or surgery, or placement of coronary stent or intraaortic balloon pump for refractory ischemia) . In addition, the absolute event rates for the primary endpoint for each subgroup are tabulated at the left (Event
  • Figure 12 is a graph illustrating the fraction of all patients with no event over the 6 month follow-up period.
  • Figure 13 is a graph illustrating the fraction of patients with no event over the 6 month follow-up period among those patients who had a successful intervention and no events until after 30 days.
  • Figure 14 is a graph illustrating the fraction of patients with no event over the 6 month follow-up period considering events after the first 48 hours among patients with an initially successful intervention.
  • Figure 15 is a graph illustrating the fraction of all patients with no attempt to revascularize the procedure related artery (PRA, procedure related artery) over the 6 month follow-up period.
  • PRA procedure related artery
  • Figure 16 is a representative graph illustrating saturation binding of 125 I-c7E3 Fab to unstimulated HUVEC. Saturation data were used to generate the Scatchard plots shown in Figures 17A-17E.
  • Figures 17A-17E are illustrations of a Scatchard analysis of saturation binding of l2S I-c7E3 Fab to: unstimulated HUVEC (Figure 17A) ; HUVEC stimulated for 4 hours with 50 units/ml of TNF ⁇ , ( Figure 17B) ; HUVEC stimulated for 24 hours with 50 units/ml of TNF ⁇ , ( Figure 17A).
  • Bound 125 I-c7E3 Fab is plotted on the abscissa and the amount bound divided by the concentration of free antibody is plotted on the ordinate. Linear regression through the curves yielded an eguation which is shown on each graph.
  • the (-) slope is defined as the K, value.
  • the intercept with the Y-axis is the B, ⁇ or maximal amount of antibody bound. Data points in each graph represent the means of triplicate determinations.
  • FIG 18 is an illustration of a Scatchard analysis of 125 I-LM609 binding to endothelial cells.
  • HUVEC were incubated with increasing concentrations of the vitronectin receptor-specific antibody l25 I-LM609 in the presence or absence of a 100-fold excess of cold c7E3 Fab to define non-specific binding.
  • the (-) slope is defined as the K, value.
  • the intercept with the Y-axis is the B ⁇ . or maximal amount of antibody bound. Data points represent the means of triplicate determinations.
  • Figure 19 is a graph illustrating competitive binding of antibodies with ,25 I-c7E3 Fab for binding to endothelial cells. HUVEC were incubated with 1 ⁇ g/ml 125 I-c7E3 in the presence of increasing concentrations of unlabeled competitor.
  • Anti-CD51 is a monoclonal antibody which recognizes the ⁇ -chain of the vitronectin receptor;
  • Anti-IIIa is a monoclonal antibody which reacts with GPIIIa; vitronectin is the native protein isolated from human plasma;
  • c7E3 Fab is chimeric 7E3 Fab fragment;
  • m7E3 IgG is murine 7E3 IgG;
  • anti-7E3 is a rabbit, variable region specific anti-7E3 antibody;
  • LM609 is a monoclonal antibody which binds to complexed ⁇ v ⁇ 3 (vitronectin receptor) but does not bind to GPIIb/IIIa;
  • 10E5 is a monoclonal antibody which reacts with GPIIb/IIIa but does not recognize endothelial cell GPIIb/IIIa;
  • chimeric MT412 is an anti-CD4 antibody used as an isotype-matched chimeric Fab fragment control.
  • FIGS. 20A-20B are histograms illustrating adhesion protein expression on endothelial cells after treatment with c7E3 Fab.
  • E-selectin expression on HUVEC after 4 hour treatment with c7E3 Fab and ICAM-1 expression on HUVEC after 24 hour treatment with c7E3 Fab was monitored by 125 I-anti-E-selectin binding (Figure 20A) or 125 l-anti-lCAM- binding ( Figure 2OB) .
  • HUVEC were treated with the indicated concentration of chimeric 7E3 Fab or chimeric MT412 Fab (an anti-CD4, isotype-matched negative control antibody) antibody for either 4 or 24 hours.
  • TNF ⁇ was used as a positive control to increase E-selectin and ICAM-1 expression.
  • Data points represent the means ⁇ SEM of triplicate determinations.
  • Figures 21A-21B are histograms illustraing PMN adhesion to endothelial cells treated with c7E3 Fab.
  • HUVEC were treated with 100 ⁇ g/ml chimeric 7E3 Fab or 100 ⁇ g/ml chimeric MT412 Fab antibody for either 4 ( Figure 21A) or 24 hours ( Figure 2IB) .
  • TNF ⁇ was used as a positive control to increase E-selectin and ICAM-1 expression and therefore adhesiveness for PMN.
  • Data represent the means ⁇ SEM of triplicate determinations.
  • the chimeric immunoglobulins of the present invention are comprised of individual chimeric heavy and light immunoglobulin chains.
  • a chimeric heavy chain comprises a nonhuman antigen-binding region (e.g., derived from the heavy chain of a nonhuman antibody specific for platelets, such as an antibody specific for the GPIIb/IIIa receptor) linked to a human heavy chain constant region.
  • a chimeric light chain comprises a nonhuman antigen binding region (e.g., derived from the light chain of the non-human antibody) linked to a human light chain constant region.
  • the present immunoglobulins can be monovalent, divalent or polyvalent.
  • Monovalent immunoglobulins are di ers (HL) formed of a chimeric heavy chain associated through disulfide bridges with a chimeric light chain.
  • Divalent immunoglobulins are tetramers (H ⁇ ) formed of two dimers associated through at least one disulfide bridge.
  • Polyvalent immunoglobulins can also be produced, for example, by employing a heavy chain constant region that aggregates (e.g., ⁇ heavy chain constant regions).
  • Chimeric immunoglobulin fragments such as Fab, Fab' or F(ab') 2 can also be produced.
  • the non-human antigen binding regions of the chimeric immunoglobulin can be derived from immunoglobulins specific for platelets.
  • Preferred immunoglobulins are specific for platelet GPIIb/IIIa receptors and can block ligand binding to the glycoprotein Ilb/IIIa receptor complex.
  • Thrombosis begins with the adhesion of platelets at sites of vessel wall injury. The adhesion of platelets is mediated by platelet surface receptors which bind to extracellular matrix proteins in the exposed subendothelium, such as von Willebrand factor, collagen, fibronectin, vitronectin, and laminin. Platelet adhesion results in a monolayer of platelets. Subsequently, platelet activation occurs in response to agonists such as epinephrine, ADP, collagen, and thrombin.
  • agonists such as epinephrine, ADP, collagen, and thrombin.
  • GPIIb/IIIa glycoprotein Ilb/IIIa receptor
  • GPIIb/IIIa glycoprotein Ilb/IIIa receptor
  • fibrinogen which can mediate platelet aggregation.
  • the binding of GPIIb/IIIa to other adhesive proteins, such as von Willebrand factor can also cause platelet cross-linking and aggregation.
  • adhesive molecules such as fibrinogen or von Willebrand factor
  • the aggregation of activated platelets is expected to be inhibited, without interfering with the initial adhesion of platelets.
  • This selective inhibition of platelet aggregation may be desirable because platelet adhesion, without aggregation, may contribute to maintaining hemostasis.
  • Suitable antibodies specific for platelets include 7E3 and 10E5. See European Patent Application Nos. EP 0,205,207, EP 0,206,532, and EP 0,206,533, the teachings of which are incorporated herein by reference.
  • the 7E3 antibody (or antibody reactive with the same or a functionally equivalent epitope) is especially preferred because it is specific for the complexed form of the
  • GPIIb/IIIa receptor Other antibodies specific for the GPIIb/IIIa receptor (antigen recognized by 7E3), such as those specific for either the lib or Ilia components, can also be used. Antibodies specific for other platelet antigens can be employed. For example, antibodies reactive with platelet ⁇ granule membrane protein GMP-140, such as S12 antibody (J. Biol. Chem.. 259:9799-9804 (1984); U.S. Patent No. 4,783,330) can be used.
  • the antigen binding region of the chimeric antibody can be derived from an immunoglobulin of nonhuman origin.
  • the antigen binding region is of murine origin because murine antibodies against platelets, and particularly GPIIb/IIIa receptors, are available or can be produced in murine systems.
  • Other animal or rodent species provide alternative sources of antigen binding regions (see e.g., Newman et al.. Bio/technology. 10: 1455-1460 (1992)).
  • the antigen binding region of the chimeric immunoglobulin comprises at least a portion of a platelet-specific immunoglobulin of nonhuman origin sufficient for specific or selective antigen binding, such as one or more complementarity determining regions or portions thereof derived from the nonhuman immunoglobulin (see e.g., Winter, U.S. Patent No. 5,225,539, European Patent No. EP 0,239,400, U.K. Patent No. 2,188,638; Adair et al . , WO 91/09967; Jolliffe et al . , WO 91/09966).
  • the chimeric immunoglobulin comprises at least one chimeric heavy chain comprising a variable region derived from the heavy chain of a nonhuman immunoglobulin, linked to at least a portion of a human heavy chain constant region, and at least one chimeric light chain comprising a variable region derived from a light chain of the nonhuman immunoglobulin covalently linked to at least a portion of a human light chain constant region.
  • variable and constant regions are also possible (see e.g., U.S. Patent No. 5,169,939).
  • the constant regions of the chimeric antibodies are derived from human immunoglobulins.
  • the heavy chain constant region can be selected from any of the five isotypes alpha, delta, epsilon, gamma or mu. Further, heavy chains of various subclasses (such as the IgG subclasses of heavy chains) are responsible for different effector functions and thus, by choosing the desired heavy chain constant region, chimeric antibodies with desired effector function can be produced.
  • Preferred constant regions are gamma 1 (IgGl) , gamma 3 (IgG3) and gamma 4 (IgG4) .
  • the light chain constant region can be of the kappa or lambda type.
  • the chimeric antibodies can be produced by preparing, for each of the light and heavy chain components of the chimeric immunoglobulin, a fused gene comprising a first DNA segment that encodes at least the functional portion of the platelet-specific variable region of nonhuman origin (e.g., functionally rearranged variable region with joining segment) linked to a second DNA segment encoding at least a part of a human constant region.
  • a fused gene comprising a first DNA segment that encodes at least the functional portion of the platelet-specific variable region of nonhuman origin (e.g., functionally rearranged variable region with joining segment) linked to a second DNA segment encoding at least a part of a human constant region.
  • Each fused gene is assembled in or inserted into an expression vector, yielding an expression vector containing a fused gene in expressible form.
  • DNA comprising the antigen binding region is covalently joined to the constant region via an intervening sequence.
  • constructs lacking one or more intervening sequences can be constructed or obtained.
  • Genes encoding the variable region of Ig light and heavy chains can be obtained from lymphoid cells that produce the platelet-specific antibodies.
  • the hybridoma cell lines that produce antibody against the GPIIb/IIIa receptor provide a source of immunoglobulin variable region for the present chimeric antibodies.
  • Other rodent cell lines are available. Cell lines can be produced by challenging a rodent with a human platelet or a GPIIb/IIIa receptor-containing component or fraction of platelets, forming fused hybrid cells between antibody-producing cells and a myeloma cell line, cloning the hybrid and selecting clones that produce antibody against platelets or glycoprotein Ilb/IIIa receptor.
  • Constant regions can be obtained from human antibody-producing cells by standard cloning techniques. Alternatively, because genes representing the two classes of light chains and the five classes of heavy chains have been cloned, constant regions of human origin are readily available from these clones.
  • Chimeric antibody binding fragments such as F(ab , ) 2 and Fab fragments can be prepared by designing a chimeric heavy chain gene in truncated form. For example, a chimeric gene encoding a F(ab') 2 heavy chain portion would include DNA sequences encoding the CH, domain and hinge region of the heavy chain. Such fragments can also be obtained by enzymatic cleavage of a chimeric immunoglobulin. For instance, papain or pepsin cleavage can generate Fab or F(ab') 2 fragments, respectively.
  • the fused genes encoding the light and heavy chimeric chains (or portions thereof) are assembled in two different expression vectors that can be used to cotransfect a recipient cell.
  • Each vector contains two selectable genes—one for selection in a bacterial system and one for selection in a eukaryotic system—each vector having a different pair of genes. These vectors allow production and amplification of the fused genes in bacterial systems, and subsequent cotransfection of eukaryotic cells and selection of the cotransfected cells.
  • selectable genes for the bacterial system are the genes that confer ampicillin resistance and the gene that confers chloramphenicol resistance.
  • gpt xanthine-guanine phosphoribosyltransferase gene
  • Tn5 Tn5
  • Selection with gpt is based on the ability of the enzyme encoded by this gene to use xanthine as a substrate for purine nucleotide synthesis; the analogous endogenous enzyme cannot.
  • a medium containing xanthine and mycophenolic acid which blocks the conversion of inosine monophosphate to xanthine monophosphate, only cells expressing the gpt gene can survive.
  • the product of the neo gene blocks the inhibition of protein synthesis in eukaryotic cells caused by the antibiotic G418 and other antibiotics of its class.
  • the two selection procedures can be used simultaneously or sequentially to select for the expression of immunoglobulin chain genes introduced on two different DNA vectors into a eukaryotic cell.
  • the preferred recipient cell line is a myeloma cell.
  • Myeloma cells can synthesize, assemble and secrete immunoglobulins encoded by transfected Ig genes. Further, they possess the mechanism for glycosylation of the immunoglobulin.
  • a particularly preferred recipient cell is an Ig-non-producing myeloma cell line such as SP2/0. These cell lines produce only the immunoglobulin encoded by the transfected immunoglobulin genes.
  • Myeloma cells can be grown in culture or in the peritoneum of mice where secreted immunoglobulin can be obtained from ascites fluid.
  • Other lymphoid cells such as B lymphocytes or hybridoma cells can serve as suitable recipient cells.
  • transfecting lymphoid cell with vectors containing immunoglobulin encoding genes A preferred way of introducing DNA into lymphoid cells is by electroporation. In this procedure recipient cells are subjected to an electric pulse in the presence of the DNA to be incorporated. See e.g., Potter et al. , Proc. Natl. Acad. Sci. USA. 8_l:716l (1984) .
  • Another way to introduce DNA is by protoplast fusion. In this method, lysozyme is used to strip cell walls from bacteria harboring the recombinant plasmid containing the chimeric Ig gene. The resulting spheroplasts are fused with myeloma cells with polyethylene glycol. After protoplast fusion, the transfectants are selected and isolated.
  • Another technique that can be used to introduce DNA into many cell types is calcium phosphate precipitation.
  • the chimeric immunoglobulin genes can also be expressed in nonlymphoid cells such as bacteria or yeast. When expressed in bacteria, the immunoglobulin heavy chains and light chains can become part of inclusion bodies. Thus, the chains must be isolated and purified and then assembled into functional immunoglobulin molecules.
  • Other strategies for expression in E. coli are available (see e.g., Pluckthun, A., Bio/Technology r 9.:545-551 (1991); Skerra, A. et al. , Bio/Technology. .9:273-278 (1991)), including secretion from E. coli as fusion proteins comprising a signal sequence.
  • the chimeric platelet-specific antibodies of this invention are useful as antithrombotic therapeutic agents.
  • the chimeric antibodies (or fragments thereof) can be used to inhibit platelet aggregation and thrombus formation in patients having a thrombus or at risk of thrombus formation.
  • the antibodies can also be used to inhibit flow variations (e.g., cyclic flow variations) which are caused by platelet aggregation, and which may precede thrombus formation or reformation.
  • the antibodies can be used in a variety of situations where thrombus formation or reformation (reocclusion) is to be prevented or minimized.
  • the antibodies can be used in a variety of situations where stenosis or restenosis is to be inhibited (reduced, delayed or prevented) .
  • patients at risk of or having coronary artery disease can benefit from the administration of an effective amount of a chimeric anti-platelet antibody or antibody fragment of the present invention (e.g., a chimeric anti-GPIIb/IIIa antibody or preferably a fragment thereof, such as chimeric 7E3 Fab or F(ab') 2 ) to inhibit occlusion, reocclusion, stenosis and/or restenosis of vessels.
  • a chimeric anti-platelet antibody or antibody fragment of the present invention e.g., a chimeric anti-GPIIb/IIIa antibody or preferably a fragment thereof, such as chimeric 7E3 Fab or F(ab') 2
  • the antibody can be administered to an individual (e.g., a mammal such as a human) to prevent thrombosis in pulmonary embolism, transient ischemic attacks (TIAs) , deep vein thrombosis, coronary bypass surgery, surgery to insert a prosthetic valve or vessel (e.g., in autologous, non-autologous or synthetic vessel graft) or deployment of a vascular (coronary or peripheral) stent.
  • an individual e.g., a mammal such as a human
  • TIAs transient ischemic attacks
  • a prosthetic valve or vessel e.g., in autologous, non-autologous or synthetic vessel graft
  • deployment of a vascular (coronary or peripheral) stent e.g., vascular (coronary or peripheral) stent.
  • the antibodies of the present invention can also be administered to an individual to prevent platelet aggregation and thrombosis before, during and/or after a coronary artery intervention procedure (e.g., angioplasty, placement of a stent, angioplasty with stent placement, vascular graft) or other vascular intervention procedures (e.g., deployment of a peripheral stent, insertion of a prosthetic valve or vessel (e.g., in autologous, non-autologous or synthetic vessel graft)) .
  • a coronary artery intervention procedure e.g., angioplasty, placement of a stent, angioplasty with stent placement, vascular graft
  • other vascular intervention procedures e.g., deployment of a peripheral stent, insertion of a prosthetic valve or vessel (e.g., in autologous, non-autologous or synthetic vessel graft)
  • the antibodies can be administered to an individual undergoing angioplasty procedures performed by balloon,
  • Antibody can be administered prior to the angioplasty procedure (pre-angioplasty) , during angioplasty, and/or post-angioplasty.
  • Such treatment can prevent thrombosis and thereby reduce the rate of thrombotic complications following angioplasty, such as death, myocardial infarction, or recurrent ischemic events necessitating PTCA or coronary bypass surgery (acute ischemic events) .
  • such treatment can yield a longer-term benefit by reduction of ischemic events or complications of a coronary artery intervention procedure (e.g.
  • angioplasty placement of a stent, angioplasty with stent placement, vascular graft) , such as death, myocardial infarction, or recurrent ischemic events necessitating PTCA or coronary bypass surgery (revascularization procedures) , indicative of reduction, delay or prevention of stenosis or restenosis.
  • a long-term reduction or prevention of ischemic events or complications due to other vascular intervention procedures e.g., deployment of a peripheral stent, insertion of a prosthetic valve or vessel (e.g., in autologous, non-autologous or synthetic vessel graft)
  • an antibody of the present invention before, during and/or after the procedure.
  • a chimeric anti-platelet antibody (chimeric 7E3 Fab fragment) as adjuvant therapy prior to angioplasty
  • Example 6 The results of a randomized, double-blind, placebo- controlled study of administration of a chimeric 7E3 antibody fragment are presented in Examples 6 and 7.
  • the data presented in Example 6 reveal that administration of chimeric 7E3 antibody fragment to patients undergoing angioplasty and at high risk of abrupt closure (reocclusion) can prevent abrupt closure (reocclusion) , decreasing the incidence of acute ischemia.
  • administration of a chimeric 7E3 antibody fragment to patients undergoing angioplasty and at high risk of abrupt closure (reocclusion) can reduce, delay and/or prevent restenosis at later times.
  • patients at risk of or having coronary artery disease can benefit from the administration of an effective amount of a compound which selectively binds to the GPIIb/IIIa receptor thereby inhibiting occlusion, reocclusion, stenosis and/or restenosis of vessels.
  • stenosis and/or restenosis of vessels can be inhibited by administering, prophylactically or therapeutically, a compound or agent (e.g., GPIIb/IIIa antagonists, immunoglobulin or non-immunoglobulin peptides or proteins (e.g., synthetic, recombinant), analogs thereof, and nucleic acids or nucleic acid analogs) which binds GPIIb/IIIa and the vitronectin receptor designated ⁇ v j8 3 .
  • a compound or agent e.g., GPIIb/IIIa antagonists, immunoglobulin or non-immunoglobulin peptides or proteins (e.g., synthetic, recombinant), analogs thereof, and nucleic acids or nucleic acid analogs
  • GPIIb/IIIa also referred to as CD41/CD61
  • CD41/CD61 belongs to a family of integrin receptors which share structural and immunological characteristics.
  • vitronectin receptor a v ⁇ 3 , also referred to as CD51/CD61
  • the vitronectin receptor is expressed on cells such as endothelial cells and vascular smooth muscle cells (and to a lesser extent, on platelets) , and mediates adhesion to a variety of extracellular matrix proteins (e.g., vitronectin, fibronectin, von Willebrand Factor, fibrinogen, osteopontin, thrombospondin, collagen, perlecan) .
  • GPIIb/IIIa The homology between GPIIb/IIIa and the vitronectin receptor is sufficient so that monoclonal antibody 7E3, directed against GPIIb/IIIa, also binds to the vitronectin receptor expressed on endothelial cells (Example 10) .
  • Injury of the vessel wall leads to the release of a variety of mediators of cellular activation and proliferation. Platelet aggregation, platelet degranulation, inversion, and platelet surface events involved in coagulation lead to thrombosis and the release of other factors (e.g., growth factors and cytokines, such as platelet-derived growth factor) , which stimulate cellular proliferation and migration at the injury site.
  • factors and cytokines such as platelet-derived growth factor
  • Inflammatory cytokines may induce the production of matrix proteins (e.g., collagen, osteopontin, vitronectin), which accumulate in the area.
  • matrix proteins e.g., collagen, osteopontin, vitronectin
  • Cellular migration is triggered, and vascular smooth muscle cells, endothelial cells, macrophages, fibroblasts, and other inflammatory cells migrate to the site, leading to a lesion (e.g., atheroma) , which narrows the vessel lumen (stenosis or restenosis) .
  • the v ⁇ 3 integrin or vitronectin receptor is implicated in the migration of cells (e.g., endothelial cells) to the site of injury.
  • ⁇ v/ S 3 binds to extracellular matrix proteins, such as vitronectin, osteopontin or other matrix proteins, present in atherosclerotic lesions.
  • Cross- linking of ⁇ v /S 3 receptors can initiate a migration/activation signal, as well as the production of substances which promote migration. Restenosis, which narrows the vessel lumen, . leads to thrombotic events.
  • an agent e.g., an antibody such as c7E3 Fab
  • an agent which reacts with both GPIIb/IIIa and ⁇ v j8 3 , and inhibits their function
  • Other events such as platelet surface events involved in coagulation, can thereby be reduced or prevented, leading to a reduction in the amount of thrombin formed and of other factors released (e.g., growth factors and cytokines) , and an inhibition of cellular proliferation, migration, and lesion formation.
  • an agent e.g., an antibody such as c7E3 Fab
  • an antibody or antibody fragment such as Fv, Fab, Fab' and F(ab') 2 fragments, which binds GPIIb/IIIa and the vitronectin receptor, can be administered.
  • Suitable antibodies can be polyclonal or monoclonal, and the term antibody or immunoglobulin is intended to encompass both polyclonal and monoclonal antibodies.
  • the term antibody or immunoglobulin is also intended to encompass single chain antibodies, chimeric, humanized or primatized (CDR-grafted) antibodies, as well as chimeric or CDR-grafted single chain antibodies, comprising portions from more than one species. See, e.g., Cabilly et al.,
  • murine 7E3 or chimeric 7E3 antibody which bind GPIIb/IIIa and the vitronectin receptor
  • the antibody to be administered is reactive with the same (or a functionally equivalent) epitope on GPIIb/IIIa and the vitronectin receptor as that bound by the 7E3 antibody.
  • an antibody which blocks the binding of the 7E3 monoclonal antibody to GPIIb/IIIa and to the vitronectin receptor can be used.
  • such a cross-reactive antibody or portion thereof has a high affinity for the GPIIb/IIIa receptor on platelets and for the vitronectin receptor on endothelial cells, for example, at least about 5.0 x 10 7 M' 1 , or more preferably at least about 1.0 x 10 8 M" 1 .
  • Such antibodies can be raised against an appropriate immunogen (e.g., platelets, isolated and/or purified GPIIb/IIIa or ⁇ v /3 3 , or their component chains, especially ⁇ 3 chain, portions of the foregoing or synthetic molecules, such as synthetic peptides) .
  • an appropriate immunogen e.g., platelets, isolated and/or purified GPIIb/IIIa or ⁇ v /3 3 , or their component chains, especially ⁇ 3 chain, portions of the foregoing or synthetic molecules, such as synthetic peptides
  • Preparation of immunizing antigen, and polyclonal and monoclonal antibody production can be performed using any suitable technique. A variety of methods have been described (see e.g., U.S. Patent No. 5,336,618 (Coller) ; Kohler et al., Nature, 256: 495-497 (1975) and Eur. J. Immunol . 6: 511-519 (1976); Milstein et al ..
  • the aggregation of platelets activates the coagulation cascade and produces a more stable fibrin meshwork and occlusive clot, which can be lysed by thrombolytic agents.
  • the antibody of the present invention or compounds which selectively bind to the GPIIb/IIIa receptor can be administered to an individual (e.g., a human) alone or in conjunction with a thrombolytic agent, such as a plasminogen activator (e.g., tissue plasminogen activator, urokinase, streptokinase, recombinant tissue plasminogen activator), or an anticoagulant (e.g., an antithrombin agent) or anti-platelet agent, such as aspirin, heparin, hirulog, hirudin, or a coumarin anticoagulant (e.g., warfarin) , to prevent or reduce reocclusion that can occur after thrombolysis and to accelerate clot lysis, for example.
  • the compounds, antibody or fragment thereof can also be administered before, along with or subsequent to administration of a thrombolytic agent, antithrombin agent, anticoagulant or anti-platelet agent, in amounts sufficient to prevent platelet aggregation that can result in occlusion or reocclusion and/or to delay or prevent stenosis or restenosis.
  • An effective amount i.e., an amount sufficient to achieve the desired therapeutic effect, such as an amount sufficient for inhibition of platelet aggregation and thereby of inhibition of thrombus formation or reformation, an amount sufficient to reduce/delay or prevent stenosis or restenosis or ischemic events
  • a compound or an antibody or antibody fragment can be given parenterally, preferably intravenously, in a pharmaceutically acceptable vehicle such as sterile saline.
  • Buffered media may be included.
  • the antibody formulation can contain additional additives, such as a stabilizer (e.g., Polysorbate 80, USP/NF) .
  • the antibody can be administered in a single dose, continuously, or in multiple infusions (e.g., a bolus injection, followed by continuous infusion) .
  • the compound or antibody could be administered by a controlled release mechanism (e.g., by a polymer or patch delivery system) or by another suitable method.
  • the amount to be administered will depend on a variety of factors such as the clinical symptoms, weight of the individual, whether other drugs (e.g., thrombolytic agents) are administered.
  • thrombocytopenia may occur; this may be a result of the body recognizing the antibody-coated platelets as foreign proteins, raising antibodies against them, and then clearing them via the reticuloendothelial system more rapidly than normal. Because of the uniguely high density of the GPIIb/IIIa receptor on the platelet surface (-80,000 receptors per platelet) and the large number of platelets in the circulation (-0.25 -0.5 X 10 6 per ⁇ l) , thrombocytopenia may be an important complication of treatment with anti-platelet antibodies.
  • the use of a chimeric anti-platelet (e.g., anti-GPIIb/IIIa) antibody can avoid this problem.
  • the chimeric anti-platelet antibodies of the present invention may minimize (reduce or prevent) the thrombocytopenia which might otherwise occur on administration of an anti-platelet antibody.
  • minimal thrombocytopenia was observed on administration of chimeric 7E3 Fab (see e.g., Examples 6 and 7).
  • chimeric 7E3 Fab antibody fragment displays a surprisingly reduced incidence of induced immunogenicity as compared with its murine counterpart (see e.g., Examples 4 and 7), particularly in view of the immunogenicity of the variable region of murine 7E3 Fab.
  • the majority of the murine component of the anti-platelet chimeric antibody will be bound to the platelet surface, e.g., via the GPIIb/IIIa receptor, and thus will be inaccessible to the immune system, rendering the chimeric antibody functionally indistinguishable from a human antibody directed against the same epitope. Therefore, other chimeric anti-platelet antibodies of the present invention may be similarly non-immunogenic in spite of their murine antigen binding region.
  • the platelet-specific chimeric immunoglobulins of this invention are also useful for thrombus imaging.
  • antibody fragments are generally preferred.
  • a chimeric heavy chain gene can be designed in truncated form to produce a chimeric immunoglobulin fragment (e.g.. Fab, Fab', or F(ab') 2 ) for immunoscintigraphic imaging.
  • Fab, Fab', or F(ab') 2 chimeric immunoglobulin fragment
  • These molecules can be labeled either directly or through a coupled chelating agent such as DTPA, with radioisotopes such as 131 Iodine, 125 Iodine, "Technetium or Indium to produce radioimmunoscintigraphic agents.
  • a radiometal binding (chelating) domain can be engineered into the chimeric antibody site to provide a site for labeling.
  • a chimeric immunoglobulin can be designed as a protein that has a nonhuman platelet-specific variable region, a human constant region (preferably truncated) , and a metal binding domain derived from a metal binding protein, such as metallothionein.
  • the platelet-specific chimeric immunoglobulin or fragment thereof is administered to a patient suspected of having thrombus.
  • the signal generated by the label is detected by means of a photoscanning device such as a gamma camera.
  • the detected signal is then converted to an image of the thrombus.
  • the image makes it possible to locate the thrombus jLn vivo and to devise an appropriate therapeutic strategy.
  • variable regions for the heavy and light chain genes from the 7E3 hybridoma were based upon the linkage in the genome between the variable region and the corresponding J (joining) region for functionally rearranged (and expressed) Ig genes.
  • J region DNA probes can be used to screen genomic libraries to isolate DNA linked to the J regions; DNA in the germline configuration (unrearranged) would also hybridize to J probes but is not linked to a variable region sequence and can be identified by restriction enzyme analysis of the isolated clones.
  • the cloning strategy therefore, was to isolate variable regions from rearranged heavy and light chain genes using J H and J ⁇ . These clones were tested to see if their sequences were expressed in the 7E3 hybridoma by Northern analysis. Those clones that contained expressed sequences were put into expression vectors containing human constant regions and transfected into mouse myeloma cells to determine if an antibody was produced. The antibody from producing cells was then tested for binding specificity and functionality in comparison with the 7E3 murine antibody.
  • accession number HB 8832 was assigned after successful viability testing.
  • the DNA was then fractionated on a 0.7% agarose gel and the DNA of size range 3-4 kb was isolated directly from the gel. After phenol/chloroform extraction and Sephadex G-50 gel filtration, the 3-4 kb fragments were ligated with lambda gtlO arms (Promega Biotech, Inc.) and packaged into phage particles jln vitro using Packagene from Promega Biotech. This library was screened directly at a density of approximately 30,000 plaques per 150 mm petri dish using a 32 P-labeled J H probe.
  • Plaque hybridizations were carried out in 5X SSC, 50% formamide, 2X Denhardt's reagent, 200 ⁇ g/ml denatured salmon sperm DNA at 42 degrees C for 18-20 hours. Final washes were in 0.5X SSC, 0.1% SDS at 65 degrees. Positive clones were identified after autoradiography.
  • variable region gene for the 7E3 light chain a genomic library was constructed in the lambda vector EMBL-3. High molecular weight DNA was partially digested with restriction endonuclease Sau3A and size-fractionated on a 10-40% sucrose density gradient. DNA fragments of 18-23 kb were ligated with EMBL-3 arms and packaged into phage particles in vitro using Packagene. This library was screened at a density of 30,000 plaques per 150 mm plate using a J yield probe. Hybridization and wash conditions were identical to those used for the heavy chain library.
  • the mouse heavy chain J H probe is a 2 kb BamHI/EcoRI fragment containing both J3 and J4 segments.
  • the mouse light chain J. probe is a 2.7 kb Hindlll fragment containing all five J ⁇ segments.
  • 32 P-labeled probes were prepared by nick translation using a kit obtained from Amersham, Inc. Free nucleotides were removed by centrifugation through a Sephadex G-50 column. The specific activities of the probes were approximately 10 9 cpm/ ⁇ g.
  • RNA 15 ⁇ g total cellular RNA was subjected to electrophoresis on 1% agarose/formaldehyde gels (Maniatis, et al, Molecular Cloning) and transferred to nitrocellulose. Blots were hybridized with nick translated DNA probes in 50% formamide, 2X Denhardt's solution, 5X SSC, and 200 ⁇ g/ml denatured salmon sperm DNA at 42 degrees for 10 hours. Final wash conditions were 0.5X SSC, 0.1% SDS at 65 degrees. DNA Transfection using Electroporation
  • Plasmid DNA to be transfected was purified by centrifuging to eguilibrium in ethidium bromide/cesium chloride gradients two times. 10-50 ⁇ g of plasmid DNA was added to 8 x 10 6 SP2/0 cells in PBS on ice and the mixture placed in a Biorad electroporation apparatus. Electroporation was at 200 volts and the cells were plated out in 96 well microtiter plates. Appropriate drug selection was applied after 48 hours and drug resistant colonies were identified after 1-2 weeks.
  • Tissue culture supernatant was analyzed for IgG protein content by particle concentration fluorescence immunoassay (Jolley, M.E. et al . , (1984) J. Immuno1. Meth. .62:21) using standard curves generated with purified IgG. Concentration of chimeric 7E3 antibody with human constant regions was determined using goat antihuman IgG Fc antibody-coated polystyrene beads and fluorescein conjugated goat anti-human IgG Fc antibody. The assay was carried out with an automated instrument (Pandex Labora ⁇ tories, Inc.) .
  • Tissue culture supernatant was concentrated with a Diaflo YM100 ultrafiltration membrane (Amicon) , and loaded onto a protein A-sepharose column.
  • the chimeric antibody was eluted from the protein A column with a sodium citrate pH gradient from pH 6.5 to pH 3.5.
  • the purified antibody was concentrated using a Diaflo YM100 ultrafiltration membrane.
  • Antibody concentration was measured by determining the absorbance at 280 nm. Binding Inhibition Assay
  • Purified antibody (either murine 7E3 or chimeric 7E3) was used to compete with radioiodinated 7E3 antibody for binding to human platelets.
  • Platelet-rich plasma (PRP) was prepared by centrifugation of citrated whole human blood at 1875 rpm for 3.5 minutes.
  • ,25 I-labeled 7E3 antibody (150,000 cpm) was added to the appropriate dilution of the purified test antibody and the reaction was initiated by the addition of 150 ⁇ l PRP. Incubation was for 1-2 hours at room temperature and the platelets with bound antibody were separated from free antibody by centrifugation through 30% sucrose at 12,000 g for 4 minutes in a 0.4 ml microfuge tube.
  • the tube tip containing the platelet/antibody pellet was cut off and counted in a gamma counter.
  • the competition for binding to platelets between iodinated 7E3 and chimeric 7E3 was compared to the competition between iodinated 7E3 and unlabeled 7E3 IgG.
  • Purified 7E3 or chimeric 7E3 antibody was added to citrated whole human blood and incubated at 37 degrees for 10 minutes. The rate of platelet aggregation was measured after activation with collagen or ADP using a whole blood aggregometer (Chronolog Corp.).
  • the DNA was transferred to nitrocellulose and the blots were hybridized with J H (heavy chain) or J, 32 P-labeled DNA probes.
  • J H heavy chain
  • J, 32 P-labeled DNA probes For the heavy chain, 2 clones were obtained that contained 3.5 kb EcoRI DNA fragments that hybridized to the J H probe. Two size classes of Hindlll fragments of 3.0 and 6.0 kb were identified with the J, probe.
  • Cloned DNA corresponding to the authentic heavy and light chain variable regions from the 7E3 hybridoma should hybridize to mRNA isolated from the hybridoma. Non-functional DNA rearrangements at either the heavy or light chain loci should not be expressed.
  • Figure 1 shows a Northern analysis that demonstrates that the 3.5 kb EcoRI putative heavy chain fragment and the 6.0 kb Hindlll putative light chain fragment each hybridizes to the appropriate size mRNA from the 7E3 hybridoma.
  • the subcloned fragments were labeled with 32 P by nick translation and hybridized to northern blots containing total RNA derived from SP2/0 (the fusion partner of the 7E3 hybridoma) or from 7E3, as indicated in Figure 1.
  • the 3.5 kb EcoRI heavy chain fragment hybridized with a 2 kb mRNA in 7E3 RNA but not in SP2/0 RNA.
  • the 6.0 kb light chain Hindlll fragment hybridized with a 1250 bp mRNA in 7E3 RNA but not in SP2/0 RNA. These are the correct sizes for heavy and light chain mRNAs, respectively. Because the cloned DNA fragments contain sequences expressed in the 7E3 hybridoma, these data suggest that the clones contain the correct variable region sequences from the 7E3 hybridoma. The final functional test, however, is the demonstration that these sequences, when combined with appropriate constant region sequences, are capable of directing the synthesis of an antibody with a specificity and affinity similar to that of the murine 7E3 antibody.
  • the putative light and heavy chain V genes cloned from the 7E3 hybridoma were joined to human K and G4 constant region genes in expression vectors described previously (Sun, L. et ____. , Proc. Natl. Acad. Sci. USA 84:214-218 (1987)).
  • the 17-1A V, Hindlll fragment of pSV184_Hneol7-lAV (t hC. was replaced with the 6.0 kb Hindlll fragment corresponding to the putative light chain variable region gene from 7E3.
  • the two plasmids were cotransfected into the nonproducing mouse myeloma cell line SP2/0.
  • the light chain plasmid confers resistance to G418 and the heavy chain plasmid confers resistance to mycophenolic acid, thus allowing a double selection to be used to obtain clones carrying and expressing genes from each plasmid.
  • Colonies resistant to G418 and mycophenolic acid were expanded to stable cell lines and maintained in the presence of both drugs. Tissue culture supernatant from these cell lines was tested for antibody using a particle concentration fluorescence immunoassay with polystyrene beads coated with goat anti-human IgG Fc antibody and the same antibody labeled with fluorescein. Out of the first 10 lines checked, one
  • FIG. 3 shows that murine 7E3 and C-7E3F6 (the putative chimeric antibody) compete with radiolabeled 7E3 for platelet binding to the same extent; the binding curves are superimposable indicating that the binding charac ⁇ teristics of murine and chimeric 7E3 are identical by this criterion.
  • C-7E3F6 was compared to murine 7E3 in a functional assay that measures the ability of the test antibody to inhibit aggregation of human platelets.
  • the results of such an assay are shown in Figure 4 and demonstrate that both antibodies inhibit collagen-induced platelet aggregation to the same extent at the same antibody concentration.
  • C-7E3F6 also inhibits ADP-induced platelet aggregation to a similar extent.
  • the results of the platelet binding assay and the inhibition of platelet aggregation assay demonstrate that: (1) the correct variable region genes were indeed cloned from the 7E3 hybridoma; and (2) the substitution of the human constant regions for the murine constant regions has no effect on the binding or functional characteristics of the 7E3 variable regions as measured by these assays.
  • the chimeric C-7E3F6 antibody was found positive in a qualitative, functional assay that measures the ability of an antibody to inhibit the agglutination between platelets and fibrinogen-coated beads. Coller, B. et __1. (1983) J. Clin. Invest. 73:325-338. Examole 2 Production of Chimeric IgGl and IgG3
  • the DNA segment encoding the variable region of the heavy chain from the murine 7E3 antibody was linked to the human 71 and 73 constant regions present on the expression vectors pSV2 ⁇ Hgptl7-lAV H -hC G1 and pSV2 ⁇ Hgptl7-lAV H -hC G3 (Sun et al., Proc. Natl. Acad. Sci. USA 84:214-218 (1987)), by replacing the 17-1A heavy or light chain variable region fragments with the corresponding 7E3 variable region fragments.
  • the resulting chimeric heavy chain genes were cotransfected with the chimeric light chain gene into SP2/0 cells to generate stable cell lines secreting 7l,K, and 73,K antibodies.
  • the Fab fragment of chimeric 7E3 was produced by enzymatic digestion of purified chimeric 7E3 IgG (gamma 1 heavy chain, kappa light chain) with the proteolytic enzyme papain.
  • the Fab fragment was isolated by a series of purification steps designed to yield a product which was free of other digestion fragments and other contaminating components (e.g., protein, nucleic acid, viruses).
  • the final product was prepared as a sterile, non-pyrogenic solution containing 2 mg of monoclonal chimeric 7E3 Fab per ml of 0.15 M sodium chloride, 0.01 M sodium phosphate, pH7.2.
  • polysorbate 80 was included at a final concentration of 0.001% (w/v). Prior to use, the product was filtered through a 0.22 micron low protein binding filter. The product was stored at 2-8 °C. Pharmacokinetics: Plasma Clearance of c7E3 Fab in Humans
  • c7E3 Fab fragment The plasma clearance of chimeric 7E3 (c7E3) Fab fragment was studied in three patients with stable coronary disease. Following a 0.20-mg/kg dose of c7E3 Fab administered intravenously as a five minute infusion, blood samples were taken at various times from two minutes to 72 hours. It was anticipated that a certain portion of the antibody would exist in an unbound state in plasma. To quantify this unbound antibody component, it was necessary to rapidly separate the plasma from the platelets to prevent further binding ex vivo. The plasma concentration of free c7E3 Fab was measured by solid-phase enzyme immunoassay (EIA) . The assay employed affinity isolated anti-murine 7E3 IgG purified from rabbit antisera for solid-phase capture and a detection system based on a biotinylated derivative of the same rabbit anti-7E3 antibody preparation. The results are presented in Table 1.
  • EIA solid-phase enzyme immunoassay
  • ND Not detected/below the detectable level of the assay (0.025 ⁇ g/mL) .
  • the theoretical maximum antibody concentration would be approximately 5.0 ⁇ g/mL (0.20 mg/kg divided by 40 mL of plasma/kg) .
  • this theoretical maximum concentration would never be attained because of the large component of injected antibody which binds to platelets.
  • the data obtained at subsequent post-injection times show a rapid initial decrease in the plasma concentration of c7E3 Fab.
  • Plasma clearance is defined as the rate of decrease in plasma concentration divided by the concentration and is computed as a rate per hour, i.e., if the rate at a given time continued for an hour, the computed rate would be the proportion of drug removed in that hour.
  • Urinary Excretion in Humans Urine samples were collected from three patients with stable coronary disease who were treated intravenously with 0.25-mg/kg of c7E3 Fab (plasma clearance data for these same three patients are discussed above) .
  • Total urine output was collected for the following post-injection time periods: 0 to 2 hours, 2 to 6 hours, 6 to 12 hours, and 12 to 24 hours.
  • a sample of predose urine was also collected. Representative samples of the collected urine samples were analyzed for free 7E3 Fab using a slight modification of the EIA described above. In all cases, no c7E3 Fab was detected in the urine.
  • Preclinical Toxicology Preclinical toxicology studies have been performed in 18 monkeys (Cyonomolgus and Rhesus) , using chimeric 7E3 Fab.
  • 7E3 was safe and well-tolerated, with no significant bleeding complications or other adverse events.
  • a dose escalation study was conducted enrolling 52 stable angina patients (males from 43 to 75 years old) who were off anti-platelet therapy for more than 10 days. A variety of dosing regimens were administered. Patients received either single intravenous bolus injections of 0.15 to 0.30 mg/kg of chimeric 7E3 Fab (20 patients) or a bolus loading followed by continuous intravenous infusions (10 ⁇ g/minute) from 12 to 96 hours in duration (32 patients) . Platelet GPIIb/IIIa receptor blockade, platelet aggregation in response to 20 ⁇ M ADP (agonist) , and bleeding times were determined 2 hours after administration of a bolus dose of c7E3 Fab (0.15-0.30 mg/kg).
  • Receptor blockade and platelet aggregation in response to agonist were determined essentially as described (Gold, H.K. et al. , J. Clin. Invest. __6 :651-659 (1990)). Bleeding times were determined by the Simplate method. With increasing doses there was a progressive increase in receptor blockade, as indicated by the percent of receptors blocked (determined from the availability of receptor binding sites) . The increase in receptor blockade was paralleled by inhibition of platelet aggregation (measured as a percent of the pre-dose value or baseline) , and by an increase in bleeding time.
  • the peak effect in terms of all three parameters was observed at 0.25 mg/kg.
  • This dose corresponds to a plasma concentration of 5 ⁇ g/ml—the concentration at which peak inhibition was seen in a platelet-rich plasma from a normal subject which had been incubated for 15 minutes in an aggregometer cuvette in the presence of increasing concentrations of chimeric 7E3 Fab.
  • the extent of aggregation of the plasma of the normal subject was measured by the percent of light transmitted through the cuvette. Prior to the addition of an agonist, the plasma was relatively opaque and the percent of light transmitted was set at zero. When the agonist ADP was added to a control sample without antibody, the light transmission progressively increased as aggregation progressed.
  • the duration of action in terms of receptor blockade, inhibition of platelet aggregation, and bleeding time was determined. Peak effects on receptor blockade, platelet aggregation, and bleeding time were seen at 2 hours, with gradual recovery over time. Bleeding times returned to near normal values by 6-12 hours. Because peak receptor blockade and functional inhibition were achieved with 0.25 mg/kg, the duration of platelet inhibition by continuous infusions following this loading dose were assayed to determine if the duration of platelet inhibition could be prolonged.
  • the treatment group included normal volunteers treated with 0.01 - 0.25 mg/kg murine 7E3 F(ab') 2 , unstable angina patients treated with 0.05 - 0.20 mg/kg murine 7E3 F(ab') 2 , and PTCA patients treated with 0.1 mg/kg murine 7E3 F(ab') 2 , or 0.15 - 0.35 mg/kg murine Fab, as well as stable angina patients treated with a single bolus intravenous injection of 0.10 - 0.30 mg/kg of murine 7E3 Fab, a single bolus dose of either 0.25 or 0.30 mg/kg followed by continuous infusion for 12-36 hours (0.15 ⁇ g/kg/min or lO ⁇ g/min) of murine Fab, or with two injections of murine Fab separated by six hours (a single bolus of 0.2 mg/kg - 0.30 mg/kg followed by a bolus of 0.05 mg/kg) .
  • Chimeric 7E3 Fab (7,, K ) has a slow off rate from platelets and free plasma chimeric 7E3 Fab clears from circulation rapidly (see above) .
  • the antiplatelet effects of chimeric 7E3 are readily reversible by administration of random donor platelets.
  • This reversal or antidote effect by transfusion of platelets has been demonstrated in 2 patients who had received either murine Fab or chimeric Fab and who received random donor platelets during a time when they had nearly complete inhibition of platlet aggregation.
  • Restoration of platelet function was determined by measuring bleeding times. This property is useful in situtations where a bleeding event necessitates restoration of platelet function in a patient.
  • Percutaneous transluminal coronary angioplasty by balloon or coronary atherectomy, for example, is an effective method of enlarging the lumen of stenosed coronary arteries.
  • PTCA Percutaneous transluminal coronary angioplasty
  • the reported rate of coronary occlusion varies from approximately 3%-6% of elective angioplasty cases (Detre, K.M. et al. , Circulation 82:739-750 (1991)), and is the major cause of in-hospital morbidity and mortality.
  • the incidence of major cardiac events caused by thrombosis is between 10-20%.
  • Acute coronary occlusion during or immediately after coronary angioplasty appears to be caused by the combination of deep arterial wall injury with resultant partially occlusive "intimal flaps" with or without superimposed thrombus formation, or thrombus formation alone at a site of vessel wall injury.
  • reocclusion after successful thrombolysis is preceded by periods of cyclical reductions and restorations in coronary blood flow termed "cyclic flow variations" (CFVs) .
  • cyclic flow variations CFVs
  • Chimeric 7E3 antibody can be used to inhibit platelet function during angioplasty thereby preventing platelet aggregation and thrombosis.
  • Chimeric 7E3 antibody is particularly useful in patients at high risk of thrombotic occlusion. These patients can be identified on the basis of anatomic (e.g., angiographically defined characteristics of a lesion at a site of stenosis) or clinical risk factors (e.g., myocardial infarction, unstable angina, diabetes, women 65 years or older) , which predispose to acute coronary thrombosis and produce the clinical syndromes of acute myocardial infarction, unstable angina or abrupt closure.
  • anatomic e.g., angiographically defined characteristics of a lesion at a site of stenosis
  • clinical risk factors e.g., myocardial infarction, unstable angina, diabetes, women 65 years or older
  • the trial was conducted in two stages.
  • the primary objective of the first stage was to determine the safety and optimal dose of single dose chimeric 7E3 Fab in patients undergoing elective percutaneous transluminal coronary angioplasy (PTCA) .
  • Stage II was conducted to evaluate the safety and preliminary efficacy of chimeric 7E3 (c7E3) when administered by bolus infusion followed by various continuous infusion durations.
  • the Stage II study comprised elective coronary angioplasty patients who were at risk for ischemic cardiac complications.
  • High risk patients included those with unstable angina or stable coronary disease with Type B or C lesion specific characteristics.
  • Table 3 lists the definitional criteria for high risk patients, and Table 4 lists the angiographically defined lesion-specific characteristics.
  • Preliminary efficacy was measured as inhibition of platelet function and prevention of thrombotic complications. Men, between 18 and 76 years of age, and women not of child bearing potential, between 18 and 76 years of age, were eligible to enroll in both stages of the trial.
  • Stage I patients were enrolled in groups receiving a single bolus intravenous injection of chimeric 7E3 (7,, K ) Fab fragment (prepared and formulated as described in Example 3) .
  • a demographic profile is listed in Tables 5A and 5B for all single dose patients and for patients within the individual dose groups.
  • Five patients (n 5) each received single doses of 0.15 mg/kg, 0.20 mg/kg or 0.25 mg/kg of c7E3 Fab within about 30 minutes prior to elective PTCA in a dose-escalation protocol.
  • the efficacy criteria for obtaining the optimal single dose of c7E3 were prospectively defined as the minimum dose that achieved median values of the following at 2 hours post-infusion: (1) prolongation of bleeding time of at least 20 minutes; (2) blockade of GPIIb/IIIa receptors such that there were greater than 80% of baseline receptor sites blocked; and (3) an inhibition of platelet aggregation in response to 20 ⁇ M ADP to ⁇ 20% of baseline.
  • CHIMERIC 7E3 ANTI-PLATELET ANTIBODY Patient Classification of Age, Weight, Height, Sex and Race
  • LCX Left circumflex coronary artery
  • LAD Left anterior descending coronary artery
  • Stage II patients were treated with a 0.25 mg/kg bolus dose followed by a continuous infusion of 10 ⁇ g/min of c7E3 Fab for 6, 12, or 24 hours.
  • a total of 32 patients (8 women and 24 men) were entered into the treatment group of Stage II of the study.
  • the median age of the c7E3 Fab-treated patients was 57 years (range 38-76) .
  • Nine control patients (l woman, 8 men) were entered.
  • the median age of control patients was 56 years (range 37-74) .
  • Control patients were high risk patients as defined above, who did not receive c7E3, but were monitored and followed in the same fashion as treated patients.
  • a demographic profile for all Stage II patients and for patients within the individual dose groups is listed in Tables 5A and 5B.
  • Treatment with c7E3 Fab was initiated 30 minutes prior to balloon inflation for PTCA.
  • Aspirin and heparin were given as clinically indicated, with the recommendation that following angioplasty heparin be given at the rate of 800 units per hour. Eleven patients each were entered into the 6 and 12 hour groups, and ten patients were entered into the 24 hour group.
  • Patient 04-006 had diabetes 2 This patient (04-007) had diabetes 3 Patients 03-001 and 02-007 had diabetes 4 This patient (04-004) had the following additional risk factors: female, age > 65, and diabetes
  • Patient 01-018 had the following additional risk factors: female and age > 65.
  • Patient 03-002 had diabetes.
  • LCX left circumflex coronary artery
  • LAD left anterior descending coronary artery
  • OM obtuse marginal branches of LCX Characteristic not designated TABLE 8B PREDISPOSING HIGH RISK CHARACTERISTICS 6-Hour Continuous Infusions
  • Type B characteristics tubular, (10 to 20mm length) ; irregular contour; ostial in location
  • LCX left circumflex coronary .artery
  • LAD left anterior descending coronary artery
  • LCX left circumflex coronary artery
  • LAD left anterior descending coronary artery
  • OM obtuse marginal branches of LCX
  • LCX left circumflex coronary artery
  • LAD left anterior descending coronary artery
  • OMn obtuse marg ⁇ inal branches of LCX TABLE 8C (cont') PREDISPOSING HIGH RISK CHARACTERISTICS 12-Hour Continuous Infusion (cont.)
  • Type B characteristic tubular 10 to 20 mm
  • LCX left circumflex coronary artery
  • LAD left anterior descending coronary artery
  • Type B characteristics a) 4 characteristics LCX (tubular; eccentric; moderate tortuosity of proximal segment; irregular contour) b) 3 characteristics LCX (eccentric; moderately angulated segment >45°, ⁇ 90°)
  • LAD eccentric; bifurcation with double guidewires
  • LCX left circumflex coronary artery
  • LAD left anterior descending coronary artery
  • Type B characteristics a) 3 characteristics LAD (irregular contour, some thrombus; bifurcation lesions requiring double guidewires) b) 1 characteristic LAD (bifurcation lesions re ⁇ quiring double guidewires) c) 2 characteristics DB (eccentric; bifurcation lesions requiring double guidewires) 5-004 1.
  • LAD anterior contour, some thrombus; bifurcation lesions requiring double guidewires
  • LAD bifurcation lesions re ⁇ quiring double guidewires
  • DB eccentric; bifurcation lesions requiring double guidewires
  • LCX left circumflex coronary artery
  • LAD left anterior descending coronary artery
  • GPIIb/IIIa receptor binding site availability (recorded as median percent GPIIb/IIIa blocked) , median inhibition of agonist-induced platelet aggregation in response to 20 ⁇ M ADP, and median bleeding times, were serially measured.
  • Receptor blockade and platelet aggregation in response to agonist were determined essentially as described (Gold, H.K. et aJL. , J. Clin. Invest... j$6_:651-659 (1990)).
  • receptor availability was measured at time 0 and the number of receptors available were taken as 0% receptors blocked (baseline) . Other time points are relative to the number of receptors available at baseline or the pre-dose measurement. Bleeding times were determined by the Simplate method.
  • Figures 6A-6C summarize the dose response 2 hours following a single bolus dose of chimeric 7E3 Fab, in terms of receptor blockade (Figure 6A) , platelet aggregation ( Figure 6B) , and bleeding time ( Figure 6C) .
  • the solid lines in Figures 6A-6C indicate the median values of the 5 patients studied at each dose group. With increasing doses of c7E3 Fab there was a progressive increase in receptor blockade as shown in percent of receptors that are blocked ( Figure 6A) . The median number of receptors blocked at two hours was 53.8% for the 0.15 mg/kg, 80.2% for the 0.20 rag/kg, and 86.6% for the 0.25 mg/kg dose groups.
  • the increase in receptor blockade was paralleled by inhibition of platelet aggregation, depicted as a percent of the pre-dose value (Figure 6B) .
  • Median platelet aggregation at 2 hours was 46.1%, 44.6%, and 17.9% of baseline for the 0.15 mg/kg, 0.20 mg/kg, and 0.25 mg/kg dose groups, respectively.
  • a dose-related prolongation of bleeding time was seen at 2 hours post-infusion (bleeding time measurements were truncated at 30 minutes; Figure 6C) .
  • the median bleeding times were 26.0 minutes, 27.5 minutes, and 30 minutes for the 0.15 mg/kg, 0.20 mg/kg, and 0.25 mg/kg doses, respectively. Under the conditions used, and as measured by these assays, the optimal dose for anti-platelet activity was determined to be 0.25 mg/kg.
  • Figures 7A-7C show the duration of action following a single bolus dose of 0.25 mg/kg, the dose at which maximum platelet effects were seen.
  • the lines indicate the median values from time zero (baseline) through 24 hours, as shown on the x-axis, in terms of receptor blockade in the top panel (Figure 7A) , platelet aggregation in the middle panel ( Figure 7B) , and bleeding time in the bottom panel ( Figure 7C) . Peak effects on recepor blockade, platelet aggregation, and bleeding time are seen at 2 hours, with gradual recovery over time. Bleeding times return to near normal values by 12 hours. None of the patients experienced thrombocytopenia.
  • Stage II Results Inhibition of Platelet Function (Stage II Results) In Stage II, GPIIb/IIIa receptor and platelet aggregation data were not obtained in all patients, and only two patients in the 24 hour infusion had these studies performed. Therefore, only the 6 and 12 hour data are summarized. In both the 6-hour and 12-hour infusion groups, median receptor blockade was maintained to greater than 80% of baseline through the duration of infusion.
  • Patient 01-019 (12-hour infusion group) had a balloon dilatation of a 95% lesion of the left circumflex coronary artery with a 50% residual narrowing. After the procedure, the patient experienced an apparent vasovagal episode, leading to bradycardia, hypotension, and transient asystole. He was returned to the catheterization laboratory and had urgent intracoronary stent placement for a persistent major longitudinal dissection. The stent became dislodged in the left main coronary artery, and the patient was sent for emergency coronary artery bypass surgery. According to the investigator, there was no evidence of intracoronary thrombosis angiographically or intraoperatively. This patient also experienced a peri-operative myocardial infarction. The patient recovered and was discharged 8 days after surgery.
  • Figure 9 shows the absolute change in hematocrit from baseline to 24 hours following the end of infusion for all patients by dose group. For reference, a line indicating the zero change point is shown. The hematocrit data from one control patient (01-022) and one c7E3 Fab-treated patient (01-019) are not plotted because both patients required blood transfusions following urgent coronary bypass surgery in the first 24 hours (see below) . A second lower line at -12 indicates the change in hematocrit needed to be designated as a minor bleed using the Thrombolysis in Myocardial Infarction (TIMI) criteria (Rao et al. , J. Am. Coll. Cardiol. .11:1-11 (1988)).
  • TIMI Thrombolysis in Myocardial Infarction
  • Stage I of this study established that c7E3 exhibits the same dose response characteristic in the PTCA population treated with aspirin and heparin as was seen in stable angina patients in a dose escalation trial (Example 3) .
  • Chimeric 7E3 produces a dose-dependent blockade of platelet GPIIb/IIIa receptors, and this receptor blockade correlates with inhibition of platelet function.
  • Stage II results demonstrate that prolonged inhibition of platelet Fab function up to 24 hours can be achieved by a continuous infusion. In all patients, platelet functional recovery begins by 6 to 12 hours after cessation of the infusion, regardless of the duration of infusion.
  • Stage II 17 treated patients had unstable angina with or without additional clinical or angiographic lesion-specific risk factors.
  • 6 patients in Stage I were identified as having unstable angina.
  • Published series have identified unstable angina patients as having a major complication (death, myocardial infarction, urgent coronary bypass surgery, or repeat PTCA) rate of 10 to 15% (De Feyter, P.J.: Editorial. Am. Heart J. 118: 860-868 (1989) and Rupprecht, H.J. et al. Eur Heart iL__ . ll.: 964-973, (1990)).
  • Angiographic characteristics similarly are highly predictive of PTCA complications (Ellis, S.G., 1990, “Elective coronary angioplasty: technique and complications", In: Textbook of Interventional Cardiology. E.J. Topol, Ed., (W.B. Saunders Co., Philadelphia); De Feyter, P.J. et aJL. , Circulation 8_3:927-936 (1991); Ellis, S.G. and Topol, E.J, Am. J. Cardiol. 6 . 6:932-937 (1990); and ACC/AHA Task Force Report: Guidelines for percutaneous transluminal coronary angioplasty, J. Am. Coll. Cardiol. 12:529-545 (1988)).
  • Stage II c7E3-treated patients met the eligibility criteria by means of lesion-specific characteristics. Of these, 12 patients had one Type B lesion, 14 had 2 or more Type B lesions, and three had Type C lesions. In addition, many of the patients in the trial had multiple lesions dilatated in a single or more than one vessel, which also potentially increases the risk of the procedure (Samson, M. et al. , Am. Heart J. 120:1-12
  • chimeric 7E3 Fab potently inhibits platelet function safely in patients treated with aspirin and intravenous heparin who are undergoing PTCA.
  • the antiplatelet action can be maintained for as long as 24 hours without a significant increase in bleeding risk and without immune system reactivity.
  • no thrombotic events occurred in the group treated with c7E3, suggesting that c7E3 can reduce the risk of thrombotic complications in this patient population.
  • the mechanism of abrupt closure is acute thrombosis at the arterial site where angioplasty has created or extended an area of endothelial injury.
  • chimeric 7E3 Fab antibody fragment was used for the treatment of abrupt coronary arterial closure complicating a coronary angioplasty procedure.
  • left ventriculography revealed overall normal left ventricular function with a very small hypokinetic area in the anterolateral left ventricular wall, and another hypokinetic area in the inferoposterobasilar zone.
  • the left ventricular ejection fraction was 72%.
  • Coronary arteriography demonstrated a left-dominant coronary system with a small and totally occluded right coronary artery.
  • a small and diffusely diseased diagonal branch originated just distal to the mid LAD stenosis.
  • the patient was returned to the coronary care unit and remained on intravenous nitroglycerin and heparin for another 48 hours. He was pain free during this time, cardiac isoenzymes did not rise, and daily EKGs revealed only the persistent flattening of the anterior precordial T waves. He was transferred to Hermann hospital (Houston, TX) for angioplasty.
  • the LAD was first instrumented with a 0.018 inch Doppler guidewire (Cardiometrics, Inc., Mountain View, CA) .
  • This guidewire is used by us routinely for flow monitoring in patients at higher risk for abrupt closure.
  • Flow-velocity signals from the LAD proximal and distal to the lesion were recorded.
  • a 2.5 mm coronary balloon catheter (Intrepid, Baxter, Inc. , Irvine, CA) was advanced over the Doppler guidewire while the wire was held stationary in the coronary artery. The balloon was positioned so that it straddled the LAD lesion. Sequential brief balloon inflations were made to 6 atmospheres pressure.
  • the severity of the stenosis was reduced as visualized by angiography as well as by increase in the flow velocity signal from a peak flow velocity (APV) of 12 cm/sec to 33 cm/sec.
  • AAV peak flow velocity
  • Chimeric 7E3 monoclonal antibody Fab fragment specific for the platelet GP Ilb/IIIa receptor (c7E3 Fab, 7,, K ) was administered. The dose was 0.25 mg per kilogram given intravenously over 1 minute. Within approximately 1 to 2 minutes after administration of c7E3 Fab, the coronary flow velocity began to increase. An injection of contrast revealed restoration of coronary patency with Thrombolysis In Myocardial Infarction Trial Grade-1 (TIMI 1) flow. Over the subsequent 15 minutes coronary flow continued to increase and stabilized at an APV of 23 cm/sec. Several other injections of contrast demonstrated improved coronary flow. The patient's chest pain subsided and the ST segment observed in the monitor lead returned to baseline.
  • TIMI 1 Myocardial Infarction Trial Grade-1
  • an angiogram was made according to protocol. This angiogram revealed TIMI3 coronary flow. The flow velocity signal at this time was 20 cm/sec. Continuous monitoring through the subsequent 5 minutes revealed no further improvement in the coronary flow. During that time the video replay of the angiogram confirmed that there was a small amount of thrombus still visible at the angioplasty site. For this reason it was decided to administer intracoronary urokinase 250,000 units. This thrombolytic agent was infused over approximately the next 10 minutes. During that time there was no further improvement in flow as measured by the Doppler guidewire.
  • the balloon catheter was again advanced over the guidewire to the site of the lesion. A final balloon inflation to 6 atmospheres for 2 minutes was then performed. Then, the balloon catheter was withdrawn while the wire remained in place. The flow signal increased to an APV of 29 cm/sec and remained stable over several minutes. An angiogram demonstrated adeguate reduction in the residual stenosis which had been present. The guidewire was then withdrawn proximal to the stenosis and another flow velocity recording was made. The guidewire, balloon catheter and guiding catheter were withdrawn. This completed the procedure.
  • the patient was then taken to the coronary care unit. He remained on oral aspirin, nitrates, a calcium channel blocking agent, and intravenous heparin for several days in order to keep the PTT in the 70-90 seconds range.
  • Serial EKGs demonstrated resolution of the anterior precordial T wave inversions and all subsequent EKGs were normal.
  • Serial creatine kinase (CK) isoenzyme values were consistently ⁇ 100 U/L.
  • the platelet count prior to the PTCA procedure was 248,000, and subsequent platelet counts at 2h, 6h, 12h, 24h, and 48h after c7E3 Fab administration were 304,000, 279,000, 246,000, 185,000 and 220,000, respectively.
  • Platelet aggregation induced by 10 ⁇ M ADP was 73% by optical densitometry prior to the procedure, and subsequent values at 2h, 6h, 12h, 24h, and 48h were 0%, 13%, 26%, 45%, and 51%, respectively.
  • the LAD coronary artery was found to be widely patent with TIMI 3 flow. He was discharged home later that same day.
  • Example 6 A Randomized. Double-Blinded. Evaluation Anti- GPIIb/IIIa Chimeric Antibody Fragment for Preventing Ischemic Complications of High Risk Angioplasty
  • c7E3 Fab reduced the risk of abrupt vessel closure during and after percutaneous intervention (see Example 4 and Ellis, S.G. et al.. Cor. Art. Dis.. 4.:167-75 (1993)).
  • the current randomized study was designed to further evaluate the efficacy of chimeric antibody fragments which bind selectively to the glycoprotein Ilb/IIIa receptor in preventing ischemic complications (EPIC trial, Evaluation of c7E3 Fab to Prevent Ischemic
  • the primary endpoint was a composite which included the occurrence of any one of the following components: death, nonfatal myocardial infarction, unplanned surgical revascularization or repeat percutaneous procedure, unplanned coronary stent implantation, or intraaortic balloon pump insertion for refractory ischemia.
  • the reduction in events achieved by administration of bolus plus infusion was consistent within each of the endpoint components, and in addition, in major patient subgroups including age, gender, preexistence of intercoronary thrombus, and acute coronary syndromes (myocardial infarction, unstable angina) . Bleeding episodes and transfusions were increased in the bolus and infusion group and intermediate for the bolus alone regimen.
  • This controlled trial of high-risk patients undergoing coronary intervention revealed that administration of an antibody fragment directed against the platelet Ilb/IIIa receptor led to sustained clinical benefit through a significant reduction in ischemic complications.
  • Angina at rest two or more episodes of angina at rest with ischemic ST segment or T wave abnormalities; or
  • Recurrent angina recurrent angina with ischemic ST segment or T-wave abnormalities while hospitalized not responsive to standard pharmacologic intervention;
  • ECG evidence of infarction defined as: a) ST segment elevation of at least 0.1 mV (measured 0.2 seconds after the J point) in at least one of three locations: i) at least 2 of 3 inferior leads (II, III, aVF) ; or ii) at least 2 of 6 precordial leads (V,-V 6 ) ; or iii) leads I and aVL; or iv) ST segment depression of the precordial leads V ] -V 4 consistent with posterior current of injury (mirror rule) ; or v) in the presence of left bundle branch block, primary ST changes in the inferior or anterior leads; b) new significant Q wave of > 0.04 seconds duration or having a depth _> one-fourth of the corresponding R wave amplitude, or both.
  • Men between the ages of 18 and 80, and women between the ages of 18 and 80, not of childbearing potential i.e., surgically sterilized or post-menopausal, defined as not having a menstrual period for at least one year.
  • Chimeric 7E3 Fab (7,, K ) was supplied as a sterile, nonpyrogenic solution containing 2 mg of monoclonal Fab per mL of 0.15 M sodium chloride, 0.01 M sodium phosphate and 0.001% polysorbate 80, pH 7.2. The only medication required at discharge was aspirin at a dose of 325 mg per day.
  • Patients were randomized equally into one of three treatment arms with a double-blind study design.
  • One group of patients was to receive a bolus of c7E3 Fab at a dose of 0.25 mg/kg followed by a 12-hour continuous infusion of c7E3 Fab at a dose of 10 ⁇ g/min.
  • a second group was to receive a bolus dose of 0.25 mg/kg c7E3 Fab and 12-hour continuous infusion of placebo solution.
  • a third group was to receive a placebo bolus and 12-hour continuous infusion of placebo solution. The bolus was started at least 10 minutes before the procedure and given over 5 minutes, and the infusion was continued for 12 hours unless a clinical contraindication developed.
  • Blood samples for platelet counts were drawn 30 minutes, 2, 12 and 24 hours following initiation of the drug and then daily until hospital discharge to carefully examine for evidence of thrombocytopenia.
  • a predesigned algorithm was used to evaluate and treat life-threatening bleeding and thrombocytopenia (Sane, D.C. et al.. Ann. Intern. Med.. 111:1010-22 (1989)).
  • the protocol contained no specific indications governing red blood cell transfusion; instead, transfusions were prescribed according to local practice patterns existing at each site.
  • Angioplasty was performed according to standard protocols. Pre- and post-procedure angiography were performed after coronary vasodilation with 150-300 ⁇ grams of intracoronary nitroglycerin.
  • vascular sheaths were maintained for at least 6 hours after the end of study agent infusion. Additionally, sheaths were left in place until at least 4 hours after the end of the heparin infusion and until an acceptable activated partial thromboplastin time was achieved to maintain hemostasis.
  • Clinical Endpoint Committee reviewed all episodes that might have represented a study endpoint or a major adverse event. This committee, which remained blinded to treatment throughout the study, reviewed the case report forms, electrocardiograms and pertinent medical records when needed. A consensus of two reviewers was required to classify an event.
  • the primary endpoint of the trial was a composite clinical endpoint including the occurrence of any one of the following events in the first 30 days after randomization: (1) Death from any cause;
  • Endpoint myocardial infarctions were defined as follows:
  • a myocardial infarction (a) a new significant Q wave > 0.04 sec in duration or with a depth ⁇ 1/4 the corresponding R wave amplitude, or both, in two or more contiguous leads; or (b) a CK or CK-MB level greater than twice the upper limit of normal.
  • Another component of the primary endpoint was the need for urgent repeat intervention, defined as an unplanned return to the angioplasty suite for intervention; planned staged procedures were not included in the primary endpoint. Similarly, only urgent coronary surgery to treat recurrent ischemia or a failed angioplasty procedure was counted as a primary endpoint.
  • Intracoronary stent placement was considered a primary endpoint when the stent was placed to treat threatened or actual abrupt closure of the vessel undergoing angioplasty.
  • Intraaortic balloon pump placement was considered to be a primary endpoint when the pump was placed for recurrent ischemia in a patient not undergoing a repeat revascularization procedure.
  • Bleeding events were classified as major, minor or insignificant using the Thrombolysis in Myocardial Infarction Study Group criteria (Rao, A.K. et al.. J. Am. Coll. Cardiol.. .11:1-11 (1988)).
  • Major hemorrhages were defined as intracranial bleeding or bleeding associated with a decrease in hemoglobin greater than 5 g/dl (or, when hemoglobin was not available, a hematocrit decrease of at least 15%) .
  • Baseline characteristics are displayed as medians and 25th and 75th percentiles for continuous variables and as percentages for discrete variables in the tables below.
  • the primary endpoint of the trial was analyzed by considering the time until the first occurrence of any one of the components of the composite endpoint within the first 30 days after enrollment. If no event occurred within the 30-day interval, the patient's follow-up was censored after 30 days.
  • Kaplan-Meier survival curves for each treatment were used to graphically display the results (Kaplan, E.L. et al.. J. Am. Stat. Assn.. 53:457-81 (1958)). All treatment comparisons were performed using the intention-to-treat principle.
  • Ml myocardial infarction. +Median (25th, 75th percentiles) Table 12 Interventional Procedural Details
  • Balloon pump 1(0.1%) 1(0.1%) 1(0.1%) 0.99
  • MI myocardial infarction
  • PTCA percutaneous angioplasty or atherectomy
  • CABG coronary artery bypass grafting.
  • MI myocardial infarction
  • Large non-Q wave MI is defined by a peak CK-MB or total CK > 5 times upper limit of normal;
  • Small non-Q wave MI is defined by a peak CK-MB or total CK 3 to 5 times upper limit of normal.
  • the timing of nonfatal ischemic events was different in the 3 groups for urgent repeat angioplasty, an event that could be timed accurately (See Figure 10) .
  • the majority of events in the placebo group occurred in the first hours after the index procedure, while a delay of several hours (-6-12 hours) until the occurrence of events was evident among the bolus group, corresponding with the time of maximal receptor blockade.
  • There was a marked delay in the onset of ischemic events in the bolus plus infusion group as well as a marked reduction in their absolute freguency.
  • the profile of bleeding complications during hospitalization is shown in Table 15. As with the primary endpoint for efficacy, a graded effect of treatment on bleeding is evident. Patients in the bolus plus infusion group displayed substantial increases in both major bleeding rate and transfusion rate, while patients receiving bolus alone displayed only a moderate increase. The majority of bleeding episodes occurred during coronary artery bypass grafting or at the site of vascular puncture in the groin, although the rate of surgical vascular repair was evenly distributed (1% in the placebo and bolus plus infusion groups and 2% in the bolus only group) .
  • Nadir platelet f 196 (159,240) 194 (153,236) 193 (154,231)
  • the frequency of secondary clinical events was low and no major differences in these outcomes were observed according to treatment.
  • the 30-day rates of heart failure (2.3%, 2.4%, 2.3%), sustained hypotension (3.0%, 3.6%, 4.1%), ventricular fibrillation (3.0%, 2.6%, 3.4%) and clinical occurrence of ischemia (21%, 17%, 18%) were similar in the placebo, bolus and bolus and infusion groups, respectively.
  • the bolus of c7E3 Fab produced a delay in the onset of these events, corresponding to length of time that platelet aggregation is affected. Four to six hours after the bolus, however, ischemic events began to occur. This interval corresponds to the period following in which platelet aggregation has been shown to return to approximately 50% of its basal value following a bolus of murine 7E3 Fab.
  • glycoprotein Ilb/IIIa receptor blockade The beneficial effect of glycoprotein Ilb/IIIa receptor blockade on clinical endpoints in the setting of high-risk angioplasty is convincing, and is consistent with the positive results of a recent initial trial using the same antibody in patients undergoing angioplasty in the setting of refractory unstable angina (Simoons, M.L. et al., J. Am. Coll. Cardiol.. 2_1:269A (1993)),
  • Severe thrombocytopenia (platelet count ⁇ 50,000/ ⁇ L) occurred in 11 (1.6%) of the patients in the bolus plus infusion treatment group and 5 (0.7%) of the patients in the placebo treatment group. Only 4 patients ( ⁇ 1%) in each of the bolus plus infusion and placebo treatment groups had both severe thrombocytopenia and serious, life-threatening, or fatal adverse events. All episodes of thrombocytopenia were transient and typically occurred during the first few days.
  • this trial demonstrates a beneficial effect of sustained blockade of the glycoprotein Ilb/IIIa receptor in patients undergoing high-risk percutaneous revascularization procedures in reducing and/or preventing reocclusion or abrupt closure.
  • This benefit was achieved at the risk of increased bleeding, consideration of the overall clinical outcomes favors this approach in the treatment of patients known to be at high risk of acute ischemic complications, based on clinical and angiographic predictors prior to the procedure.
  • the trial provides the first validation of a meaningful therapeutic approach to inhibition of the function of cell integrins, paving the way for other selectin and integrin targets for biotechnology in the future, as well as non-antibody or peptide approaches to this specific Ilb/IIIa glycoprotein.
  • the ajor biologic trigger of restenosis is vascular injury, induced by the inflated balloon or alternative device at the site of intervention, and accompanied by platelet- thrombus formation and change of phenotype of medial smooth muscle cells from their resting, contractile state to one capable of migratory, proliferative and secretory function (Forrester, J.S. et al.. J. Am. Coll. Cardiol. P 17:758-769 (1991); Ip, J.H. et al.. J. Am. Coll. Cardiol.. r7:77B-88B (1991); Casscells, W. , Circulation. 8.6.723-729 (1993)).
  • Coronary angioplasty is routinely performed with adjunctive oral aspirin and intravenous heparin.
  • This anti-thrombotic approach is only weakly inhibitory of platelet aggregation.
  • a variety of agonists including thrombin, collagen, and adenosine diphosphate can stimulate platelets even in the face of aspirin therapy.
  • Molecular biology of the platelet has elucidated the glycoprotein Ilb/IIIa integrin as the receptor responsible for platelet aggregation (Plow, E.F. et al.. Prog. Hemostas. Thromb. , 296:320-331 (1988); Coller, B.S., J. Clin. Invest.. 2J5:101-108, (1985)).
  • the chimeric 7E3 antibody Fab fragment binds selectively to the platelet Ilb/IIIa integrin.
  • a multicenter, double-blind, placebo-controlled trial in 2,099 patients was performed (see Example 6) .
  • c7E3 is capable of reducing the incidence of clinical restenosis, as defined by ischemic events or the need for repeat revascular ⁇ ization during the subseguent 6-month follow-up phase.
  • Example 6 Methods Details of the study population and protocol are described in Example 6. To recapitulate, patients were eligible if they were undergoing coronary angioplasty or directional atherectomy and had an evolving or recent myocardial infarction, unstable angina, or high risk angiographic lesion morphology as defined by the American Heart Association/American College of Cardiology criteria (ACC/AHA Task Force Report, J. Am. Coll. Cardiol.. 12:529- 545 (1988)). Exclusion criteria were bleeding diathesis, age > 80 years, stroke within 2 years, or major surgery within 6 weeks. The protocol was approved by the
  • Intravenous heparin was given during the procedure to achieve an activating clotting time of at least 300 seconds.
  • patients were randomly assigned to one of three alternative regimens: (1) placebo bolus and placebo 12 hour infusion; (2) active c7E3 (Centocor, Malvern, PA) bolus at 0.25 mg/kg and placebo 12 hour infusion; or (3) active c7E3 bolus at the same dose followed immediately by c7E3 infusion at 10 ⁇ g/min for 12 hours. The bolus was given at least 10 minutes prior to the coronary intervention procedure.
  • the primary endpoint was the 30-day composite incidence of death from any cause, myocardial infarction, coronary artery bypass surgery for acute ischemia, repeat percutaneous coronary intervention for acute ischemia, need for an endoluminal stent or insertion of an intra-aortic balloon pump to treat ischemia. All of these events were reviewed by an independent Clinical Endpoints Committee which remained blinded to treatment throughout the study and required consensus of at least two reviewers for classification.
  • the criteria for diagnosis after hospital discharge of myocardial infarction required either a new significant Q-wave > 0.04 sec in duration or with a depth > 1/4 the corresponding R wave amplitude in two or more contiguous leads; or creatine kinase or creatine kinase myocardial band greater than twice the upper limit of normal.
  • Resvascularization data were collected as well as whether the original target vessel was subjected to repeat surgical or percutaneous revascularization.
  • follow-up was 97.2% complete.
  • the analysis included all events from baseline to 6 months, events occurring after the 30 day endpoint in patients with an initial successful intervention (defined as achievement of a final stenosis less than 50% according to the reading of the clinical investigator and without an ischemic complication) , and events occurring after 48 hours in patients with an initial successful intervention.
  • the 30-day endpoint was prospectively selected because of precedence in many cardiovascular intervention trials.
  • the 48 hour cutoff was used because it is known that, by definition, nearly all abrupt closure events that occur following coronary intervention take place within this time window (Detre, K.M. et al.. J. Am. Coll. Cardiol.. H:230A (1989);
  • Randomization was performed via a telephone call to the Duke Coordinating Center and stratified by study site and whether the patient was having an acute myocardial infarction. Data were collected by study coordinators on a separate 6 month case report form that was quality assured by source documentation by blinded study monitors prior to data entry. The sponsor remained blinded to the follow-up results until all patients had completed follow-up, the events were adjudicated by the Endpoints Committee, and the database was complete.
  • HACA human anti- chimeric antibody
  • the monoclonal Fab fragment used in the trial has potent affinity for binding to the platelet Ilb/IIIa surface integrin with minimal dissociation.
  • Previous studies in patients undergoing angioplasty with c7E3 have shown that even after the infusion of the antibody is terminated, there is persistent occupancy of the Ilb/IIIa binding sites for at least 36 to 48 hours, and evidence of inhibition of platelet aggregation for at least 72 hours (see Example 4; see also, Ellis, S.G. et al.. Cor. Art. Dis.. 4 . :1675-175 (1993); Tcheng, J.E. et al.. Circulation. j$8_: (1993)).
  • c7E3 has been reported to bind to the vitronectin receptor (Hynes, R.O., Cell. 69:11- 25 (1992)), probably because this receptor contains the ⁇ 3 component of GPIIb/IIIa.
  • This integrin (vitronectin) may have a role in modulating stenosis or restenosis, and binding of anti-GPIIb/IIIa to the vitronectin receptor may contribute to the effect observed.
  • Other GPIIb/IIIa receptor inhibitors have varying degrees of specificity for the target and for homologous integrins (Sutton, J. et al. , Clinical Research AFCR. 4_i:118A (1993)).
  • Bleeding complications were assessed in the EPIC trial (see Examples 6 and 7) to determine if sheath size during PTCA/DCA correlates with bleeding complications .
  • Sheath and guiding catheter size were determined clinically by the interventionalist. Major bleeding episodes, groin bleeding, transfusion, vascular repair, nadir Hct were prospectively assessed.
  • Major bleeds (10.5%), transfusions (11.8%), and nadir Hct (34) did not vary with sheath size.
  • c7E3 Fab patients had more groin bleeds than non-7E3 patients (55% vs. 30%, p ⁇ 0.0001) .
  • bleeding indices nodir hematocrit, bleeding index, change in hematocrit, units of packed red cells transfused
  • the primary endpoint of the study death, myocardial infarction, coronary artery bypass grafting (CABG) or PTCA for acute ischemia or insertion of a coronary stent for procedural failure
  • This association was also present for each of the therapies: placebo, bolus c7E3 Fab, and bolus plus infusion c7E3 Fab.
  • This strong relationship may be due to the increased bleeding associated with primary endpoint events (e.g. CABG) .
  • primary endpoint events e.g. CABG
  • bleeding with associated hypotension may be a major contributor to post-procedural ischemic complications.
  • patients who developed hypotension (excluding hypotension after a primary outcome event) after successful PTCA were significantly more likely to have a primary outcome event and were also more likely to experience major bleeding and a primary outcome event.
  • bleeding appears to induce ischemic complications in some patients, and measures to reduce bleeding (for example, modifications of heparin dosage) may further enhance the anti-ischemic efficacy of GPIIb/IIIa inhibition for coronary intervention.
  • the activated clotting time has been used during percutaneous transluminal coronary angioplasty (PTCA) to monitor the extent of thrombin inhibition and anticoagulation in an attempt to minimize untoward thrombotic events.
  • PTCA percutaneous transluminal coronary angioplasty
  • potent platelet inhibitors such as chimeric monoclonal antibody c7E3 Fab
  • the utility of measuring and regulating ACT during PTCA has not been examined.
  • an effect of c7E3 on ACT was not known or suspected.
  • the possible influence of platelet GPIIb/IIIa antagonism on procedural ACT was investigated. In the trial, 2099 subjects undergoing PTCA were randomized to receive placebo
  • the activated clotting time is increased 35- 40 seconds by the platelet GPIIb/IIIa antagonist c7E3 Fab. This has important implications for dosing conjunctive heparin therapy and performing coronary artery interventions in the setting of GPIIb/IIIa-directed therapy.
  • PTCA percutaneous intervention
  • 125 I-murine 7E3 IgG (m7E3 IgG) was prepared by iodogen labelling. Specific activity and protein concentrations were determined to be 4.1 ⁇ Ci/ ⁇ g and 45 ⁇ g/ml, respectively. A 1:20 dilution was made with HSA-saline diluent (0.1% human serum albumin in 0.9% NaCl solution) to yield 100,000 cpm/10 ⁇ l.
  • 125 I-chimeric 7E3 Fab (c7E3 Fab) was also prepared by iodogen labelling. The specific activity and protein concentrations were 0.995 ⁇ Ci/ ⁇ g and 0.29 mg/ml, respectively.
  • a 1:62.5 dilution was made with HSA-saline diluent to yield 100,000 cpm/10 ⁇ l.
  • Platelet Rich Plasma was prepared according to standard procedures. Blood was collected into sodium citrate anticoagulant and PRP was adjusted to 200-300,000 platelets/ ⁇ l and used within an hour.
  • Antibody binding was performed by a modification of the method described by Coller (Coller, B.S., J. Clin.
  • the fraction of bound antibody was calculated by using the radioactive counts measured in the pellet and supernatant. It was assumed that the binding of radioactively labelled antibody was identical to that of cold antibody and that the value of the bound antibody fraction calculated from labelled antibody was representative of the entire population of antibody molecules.
  • This bound antibody (Ab) fraction, together with values for the total concentration of antibody ([Ab]) were used to calculate the molar concentrations of bound and free antibodies for each data point.
  • First a binding isotherm plot was drawn by plotting [Bound Ab] versus [Free Ab] .
  • a four parameter curve was fitted by KaleidaGraph software (Synergy Software, Reading, PA) in a Macintosh computer.
  • m4 an exponent related to the slope of the linear portion of the curve.
  • Kd [Ab] x [Ag] / [Ab:Ag] where [Ab] , [Ag] and [Ab:Ag] are equilibrium molar concentrations of free Ab, free Ag and Ab:Ag complex.
  • Binding of c7E3 Fab to human platelets follows a con ⁇ ventional binding pattern.
  • the binding isotherm revealed a smooth predicted curve expected from binding of a homogenous monoclonal Ab Fab fragment to homogenous cell surface antigen.
  • the dissociation and association constants of the reaction were calculated to be 5.15 nanomolar and 1.94E08 M" 1 , respectively.
  • the number of GPIIb/IIIa antigens present on the platelet surface was determined to be 69590 (-70,000).
  • m7E3 IgG binds to platelets with dissociation and association constants of 3.56 nanomolar and 2.81E08 M" 1 , respectively.
  • the GPIIb/IIIa density calculated for 7E3 IgG was found to be 73,355 epitopes/platelet. These numbers indicate that intrinsic reaction constants of the antigen binding sites of 7E3 Fab and 7E3 IgG are similar. It was concluded that m7E3 IgG binds to platelets with both arms based on an analysis of this data and consideration of the off rate constants.
  • Platelet glycoprotein GPIIb/IIIa belongs to a family of integrin receptors which share structural and immunological characteristics.
  • An integrin closely related to GPIIb/IIIa is the vitronectin receptor (a v ⁇ 3 ) which utilizes the same ⁇ subunit as GPIIb/IIIa but has a different o subunit.
  • the vitronectin receptor is expressed on endothelial cells and mediates adhesion to a variety of extracellular matrix proteins (e.g., vitronectin, fibronectin, von Willebrand Factor, fibrinogen, osteopontin; thrombospondin, collagen, perlecan) .
  • the antibodies used in these studies included the following: Anti-GPIIb/IIIa chimeric 7E3 Fab (C-116E; an IgGl Fab produced by papain digestion) ; anti-CD4 chimeric MT412 Fab used as an isotype-matched chimeric Fab fragment control (produced by cell line C128A; published International application number WO 91/10722) ; anti-E-selectin H18/7 F(ab') 2 (gift of M. Bevilaqua) ; anti-ICAM-1 #19 (gift of G.
  • anti-CD51 AMAC
  • anti-IIIa AMAC
  • murine 7E3 IgG AMAC
  • anti-7E3 is a rabbit, variable region specific anti-7E3 polyclonal antibody preparation
  • monoclonal antibody LM609 gift of D. A. Cheresh, Scripps Research Institute, La Jolla, CA
  • Chimeric 7E3 Fab and chimeric anti-CD4 MT412 Fab were filtered through a 0.22 micron, 13 mm filter unit (Millipore, Millex-GV #SLGV01305) prior to radiolabeling.
  • Antibodies were radiolabeled with Na 125 I (Amersham) using Iodobeads (Pierce Chemicals, Rockford, IL) and passed through a Sephadex G25 column (Pharmacia PD-10 Sephadex G-25M) , to remove unreacted ,2S I-iodide.
  • the column had been blocked previously with 0.1% human serum albumin (Albuminar-25, Armour Pharmaceutical Co., Kankakee, IL) in phosphate buffered saline and equilibrated with 0.01% Tween 80-PBSS elution buffer.
  • Antibodies were 0.22 micron filtered after iodinaton and antibody concentration determined by measuring the absorbance at 280 nm and using 1.5 OD/mg mL "1 as the absorptivity coefficient.
  • HUVEC at passage 1 were purchased from Cell Systems (Kirkland, WA) and cultured with serum-containing media (HUVEC media, Cell Systems) in 2% gelatin-coated tissue culture flasks until passage 4 at which time they were frozen at 5 x 10 6 cells/ml.
  • serum-containing media HUVEC media, Cell Systems
  • cells were thawed and seeded directly at -1 x 10 4 cells/well into 2% gelatin-coated
  • HUVEC were seeded into 96-well removacell tissue culture plates (Dynatech) and grown to confluence.
  • 125 I-c7E3 Fab was diluted in HUVEC media containing 10% FCS (or serum free media if indicated) .
  • One set of cells was incubated with tracer in the presence of 0.02% sodium axide to prevent capping and internalization of tracer antibody.
  • a 100-fold excess of cold c7E3 Fab was used to define non-specific binding.
  • the cells were incubated with tracer for 4 hours at 37°C, washed with 2 x 200 ⁇ l of media, and the wells were removed and radioactivity bound was guantitated using a gamma counter.
  • the number of cells per well was quantitated by trypsinization of sample wells and counting of cells using a hemacytometer. Assays were performed in triplicate determinations. For Scatchard data analysis, bound
  • 125 I-c7E3 was plotted on the abscissa and the amount bound divided by the concentration of free antibody was plotted on the ordinate.
  • a linear regression through the curve yielded a (-) slope which was defined as the K a value.
  • the intercept with the X-axis was defined as the B. ⁇ . or maximal amount of antibody bound.
  • the B ⁇ value was converted to sites per cell using the following formula:
  • HUVEC E-selectin and ICAM-1 expression HUVEC were seeded into 96-well pop-out well tissue culture plates and grown to confluence. Cells were treated in 100 ⁇ l of HUVEC complete media containing the indicated concentration of antibody for either 4 or 24 hours. TNF ⁇ (Genzyme) at 50 units/ml was used as a positive control to increase E-selectin and ICAM-1 expression. After incubation, media was removed and replaced with 50 ⁇ l of HUVEC complete media containing 1 ⁇ g/ml ,25 I-anti-E-selectin antibody (for the cells stimulated for 4 hours) or 1 ⁇ g/ml 125 I-anti-ICAM-l antibody (for the cells stimulated for 24 hours) . The cells were incubated for 1 hour at 37°C, washed with 2 x 200 ⁇ l of media, the wells were removed and radioactivity bound was quantitated with a gamma counter.
  • TNF ⁇ Gene
  • HUVEC were seeded into 96-well pop-out tissue culture plates and grown to confluence. Cells were treated in 100 ⁇ l of HUVEC complete media containing the indicated concentration of antibody for either 4 or 24 hours.
  • TNF ⁇ Gene
  • TNF ⁇ Gene
  • PMNs polymorphonuclear leukocytes
  • PMN were isolated from heparinized human blood using Monopoly Resolving Medium (Flow Labs) . PMN were resuspended in 5 ml of RPMI and "'Indium labeled for 15 minutes at room temperature with 100 ⁇ l U1 lndium (Amersham) .
  • the cells were washed twice with 50 ml of RPMI and resuspended to 4 x 10 6 /ml in RPMI containing 10% FCS. Media was removed from the HUVEC monolayer and 100 ⁇ l of PMN were added to each well and incubated for 30 minutes at 37°C. Unbound PMNs were removed by 2 x 200 ⁇ l washes with media. Bound PMNs were quantitated by counting of the wells in a gamma counter. The experiment was done with triplicate determinations.
  • HUVEC were seeded into 2% gelatin coated T-150 flasks and used when -85% confluent. Cells were briefly trypsinized, washed, and resuspended in HUVEC complete media at 3 x 10 5 cells/ml. The cells were treated with either c7E3 Fab or cMT412 Fab at 10 ⁇ g/ml and immediately seeded at 300 ⁇ l/well into either glass 8-chamber slides (NUNC #177402) or Permanox plastic 8-chamber slides (NUNC #177445) or 48-well tissue culture plastic plates (Corning) and placed in a 37°C C0 2 humidified incubator.
  • NUNC #177402 glass 8-chamber slides
  • NUNC #177445 Permanox plastic 8-chamber slides
  • 48-well tissue culture plastic plates (Corning) and placed in a 37°C C0 2 humidified incubator.
  • fibronectin at 20 ⁇ g/ml Sigma F2006
  • fibrinogen at 40 ⁇ g/ml Sigma F4883
  • vitronectin at 20 ⁇ g/ml Sigma V8379
  • HUVEC HUVEC were incubated with increasing concentrations of l25 I-labeled c7E3 Fab in the presence or absence of a 100-fold escess of cold c7E3 Fab to define non-specific binding. Data were analyzed using Scatchard analysis as described above.
  • a rabbit, variable region specific anti-7E3 antibody also blocked 125 I-c7E3 Fab binding with an IC J0 value of approximately 1.0 ⁇ g/ml.
  • An isotype-matched control Fab fragment MT412 (anti-CD4) did not compete for ,25 I-c7E3 Fab binding.
  • the 10E5 antibody which reacts with GPIIb/IIIa but does not recognize endothelial cell "GPIIb/IIIa" also did not compete.
  • An anti- ⁇ v antibody (clone AMF7 purchased from AMAC) and an anti-IIIa antibody (clone SZ.21 purchased from AMAC) and the vitronectin protein did not compete for 125 I-c7E3 Fab binding.
  • Endothelial cells can be activated by LPS, IL-1, and TNF ⁇ to express adhesion proteins such as E-selectin and ICAM-1. These adhesion proteins mediate the adhesion of leukocytes to the endothelium and allow their transmigration to sites of inflammation.
  • adhesion proteins such as E-selectin and ICAM-1.
  • E-selectin and ICAM-1 mediate the adhesion of leukocytes to the endothelium and allow their transmigration to sites of inflammation.
  • 4 hours of exposure to an activating agent provides a stimulus for optimal expression of E-selectin, and 24 hours of incubation is optimal for ICAM-1 expression.
  • Incubation of HUVEC for either 4 or 24 hours with c7E3 Fab did not change either E-selectin or ICAM-1 expression ( Figures 20A-20B) as measured by 125 I-antibody binding.
  • Chimeric 7E3 Fab treatment (0.01, 0.1, 1.0, 10, or 100 ⁇ g/ml) or control Fab treatment (1.0, 10, or 100 ⁇ g/ml chimeric MT412 Fab) of HUVEC also did not significantly increase adhesiveness of the HUVEC for PMN ( Figures 21A-21B; 100 ⁇ g/ml shown) .
  • the cells treated for 4 or 24 hours with up to 100 ⁇ g/ml c7E3 Fab did not look any different from untreated cells, either before or after washing the monolayer.
  • HUVEC Effect of c7E3 Fab on spreading and adhesion of HUVEC to substrate-coated surfaces
  • HUVEC were treated with either (1) media alone and seeded on vitronectin-coated glass or plastic, or (2) were treated with chimeric 7E3 Fab (10 ⁇ g/ml) and seeded on (a) vitronectin-coated glass or plastic, (b) fibrinogen-coated glass or plastic, or (c) fibronectin-coated glass or plastic.
  • cells were seeded onto chamber slides or 48-well tissue culture plates, and incubated at 37°C. Phase contrast photomicrographs were taken at 6 hours after seeding with an inverted phase contrast microscope.
  • Untreated cells which were seeded on fibrinogen or fibronectin-coated plastic looked similar to untreated cells grown on vitronectin-coated plastic.
  • Chimeric MT412-treated cells looked like untreated cells.
  • c7E3 Fab addition on HUVEC adhesion and spreading after 6 hours to fibronectin, vitronectin, or fibrinogen coated Permanox plastic, glass, or tissue culture plastic. There was also no effect seen at 24 hours after cell seeding.
  • the affinity of c7E3 did not change in the presence of azide, indicating that internalization of the antibody did not occur.
  • the affinity was also the same in serum-free media, suggesting that proteins in fetal calf serum did not alter the binding of c7E3 Fab to endothelial cells.
  • Approximately 650,000 c7E3 Fab molecules bind to each endothelial cell and 80-100,000 c7E3 Fab molecules bind each platelet.
  • vitronectin receptors on endothelial cells measured by saturation binding with a vitronectin receptor-specific antibody was - 300,000. This was half the number of sites bound by c7E3 Fab. This discrepancy could be attributed to the increased ability of the smaller c7E3 Fab to reach receptor sites unavailable to the LM609 IgG or bivalent binding of the LM609 IgG antibody.
  • Binding of c7E3 Fab did not appear to activate endothelial cells as measured by the upregulation of E-selectin or ICAM-1 adhesion proteins or by the ability of endothelial cells to bind PMNs. Binding of c7E3 Fab to endothelial cells immediately before seeding them onto vitronectin, fibronectin, or fibrinogen coated glass or plastic did not alter the cells' ability to spread and adhere to the surfaces. This finding is different from a previous report of inhibition by m7E3 IgG (20 ⁇ g/ml) of HUVEC adherence and spreading on fibrinogen- and vitronectin- coated glass (Charo et al . , J. Biol . Chem .
  • chimeric 7E3 Fab binds to endothelial cell vitronectin receptors in vitro .
  • the antibody appears to bind specifically to endothelial cells through the vitronectin receptor ( ⁇ v /3 3 ) , since an ⁇ v 3 3 -specific antibody LM609 inhibited c7E3 Fab binding completely.
  • c7E3 Fab The binding of c7E3 Fab to endothelial cells did not appear to activate the cells, as assessed by the expression of activation-specific markers. In particular, E-selectin and intercellular adhesion molecule-1 (ICAM-1) expression was not increased upon treatment with c7E3 Fab.
  • IAM-1 intercellular adhesion molecule-1
  • Binding of the antibody does not appear to disrupt endothelial cell monolayers or prevent their establishment on matrix protein-coated surfaces. Exposure of HUVEC to c7E3 Fab did not alter the ability of HUVEC to spread and adhere to vitronectin, fibronectin, or fibrinogen coated surfaces. In addition, adhesiveness of human umbilical vein endothelial cells (HUVEC) for polymorphonuclear leukocytes (PMN) was not enhanced by antibody treatment. In summary, c7E3 binds to the vitronectin receptor on endothelial cells in vitro, and this binding appears not to activate the cells or affect their ability to adhere and spread on matrix proteins.
  • HUVEC human umbilical vein endothelial cells
  • PMN polymorphonuclear leukocytes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des agents qui se lient de manière sélective à la GPIIb/IIIa et au récepteur de vitronectine et peuvent s'utiliser pour réduire ou prévenir les phénomènes d'occlusion, de réocclusion (par ex. fermeture soudaine), de sténose et/ou de récidive de sténose. Dans une variante, une immunoglobuline ou un fragment d'immunoglobuline, telle qu'une immunoglobuline chimérique spécifique des plaquettes ou un de ses fragments comprenant une région non humaine de liaison d'antigène et une région humaine constante, est utilisée dans le procédé.
PCT/US1996/010216 1995-06-07 1996-06-05 Immunoglobuline chimerique specifique des plaquettes et procedes d'utilisation WO1996040250A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU63323/96A AU6332396A (en) 1995-06-07 1996-06-05 Platelet-specific chimeric immunoglobulin and methods of use therefor
JP9502244A JPH11511120A (ja) 1995-06-07 1996-06-05 血小板特異的キメラ免疫グロブリン及びその使用方法
EP96922452A EP0835135A2 (fr) 1995-06-07 1996-06-05 Immunoglobuline chimerique specifique des plaquettes et procedes d'utilisation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47552695A 1995-06-07 1995-06-07
US08/475,526 1995-06-07

Publications (2)

Publication Number Publication Date
WO1996040250A2 true WO1996040250A2 (fr) 1996-12-19
WO1996040250A3 WO1996040250A3 (fr) 1997-01-23

Family

ID=23887963

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/010216 WO1996040250A2 (fr) 1995-06-07 1996-06-05 Immunoglobuline chimerique specifique des plaquettes et procedes d'utilisation

Country Status (7)

Country Link
EP (1) EP0835135A2 (fr)
JP (1) JPH11511120A (fr)
CN (1) CN1186439A (fr)
AU (1) AU6332396A (fr)
CA (1) CA2223885A1 (fr)
NZ (1) NZ513882A (fr)
WO (1) WO1996040250A2 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033919A3 (fr) * 1997-01-30 1998-12-17 Ixsys Inc Anticorps anti-alpha-v beta-3 humanises de recombinaison, acides nucleiques codant lesdits anticorps et leurs procedes d'utilisation
WO2000026256A2 (fr) * 1998-11-03 2000-05-11 Centocor, Inc. Anticorps et fragments d"anticorps modifies avec une duree d"activite accrue
WO2000066160A1 (fr) * 1999-04-28 2000-11-09 Yamanouchi Pharmaceutical Co., Ltd. Composition medicamenteuse parenterale a fragment d'anticorps monoclonal humanise et procede de stabilisation
US6531580B1 (en) 1999-06-24 2003-03-11 Ixsys, Inc. Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same
US6596850B1 (en) 1998-01-30 2003-07-22 Ixsys, Incorporated Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same
EP2789631A1 (fr) * 2013-04-10 2014-10-15 Synapse B.V. Composés et procédés pour l'inhibition de liaison ICAM-4 vers de l'intégrine plaquettaire alphaIibbeta3

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP783198A0 (en) * 1998-12-21 1999-01-21 Resmed Limited Determination of mask fitting pressure and correct mask fit
CA2558064A1 (fr) * 2004-02-25 2005-09-01 Astellas Pharma Inc. Produit de contraste pour la formation d'un thrombus

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012734A1 (fr) * 1991-01-17 1992-08-06 The Board Of Regents Of The University Of Washington Anticorps contre les facteurs de croissance dans le traitement de la stenose vasculaire
US5318899A (en) * 1989-06-16 1994-06-07 Cor Therapeutics, Inc. Platelet aggregation inhibitors
WO1995012412A1 (fr) * 1993-11-05 1995-05-11 Centocor, Inc. Immunoglobuline chimerique specifique des plaquettes et son procede d'utilisation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5318899A (en) * 1989-06-16 1994-06-07 Cor Therapeutics, Inc. Platelet aggregation inhibitors
WO1992012734A1 (fr) * 1991-01-17 1992-08-06 The Board Of Regents Of The University Of Washington Anticorps contre les facteurs de croissance dans le traitement de la stenose vasculaire
WO1995012412A1 (fr) * 1993-11-05 1995-05-11 Centocor, Inc. Immunoglobuline chimerique specifique des plaquettes et son procede d'utilisation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J. CARDIOVASCULAR PHARMACOLOGY, vol. 23, no. 2, 1994, pages 194-202, XP002019168 WILLIAM E. ROTE ET AL.: "Prevention of Rethrombosis After Coronary Thrombolysis in a Chronic Canine Model. I. Adjunctive Therapy with Monoclonal Antibody 7E3 F(ab')2 Fragment" *
THROMBOSIS AND HAEMOSTASIS, vol. 74, no. 1, - July 1995 pages 302-308, XP002019167 BARRY S. COLLER ET AL.: "New Antiplatelet Agents: Platelet GPIIb/IIIa Antagonists" *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6590079B2 (en) 1997-01-30 2003-07-08 Ixsys, Incorporated Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
US7422744B2 (en) 1997-01-30 2008-09-09 Applied Molecular Evolution, Inc. Methods of treating cancer with alphavbeta3-specific antibodies
WO1998033919A3 (fr) * 1997-01-30 1998-12-17 Ixsys Inc Anticorps anti-alpha-v beta-3 humanises de recombinaison, acides nucleiques codant lesdits anticorps et leurs procedes d'utilisation
US6596850B1 (en) 1998-01-30 2003-07-22 Ixsys, Incorporated Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same
US7422745B2 (en) 1998-01-30 2008-09-09 Applied Molecular Evolution, Inc. Methods of treating cancer with vαβ3-specific antibodies
WO2000026256A3 (fr) * 1998-11-03 2001-11-08 Centocor Inc Anticorps et fragments d"anticorps modifies avec une duree d"activite accrue
WO2000026256A2 (fr) * 1998-11-03 2000-05-11 Centocor, Inc. Anticorps et fragments d"anticorps modifies avec une duree d"activite accrue
WO2000066160A1 (fr) * 1999-04-28 2000-11-09 Yamanouchi Pharmaceutical Co., Ltd. Composition medicamenteuse parenterale a fragment d'anticorps monoclonal humanise et procede de stabilisation
US6531580B1 (en) 1999-06-24 2003-03-11 Ixsys, Inc. Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same
US7371382B2 (en) 1999-06-24 2008-05-13 Applied Molecular Evolution, Inc. Methods of inhibiting αvβ3-mediated binding with αvβ3-specific antibodies
US7667007B2 (en) 1999-06-24 2010-02-23 Applied Molecular Evolution, Inc. αvβ3-specific antibodies
EP2789631A1 (fr) * 2013-04-10 2014-10-15 Synapse B.V. Composés et procédés pour l'inhibition de liaison ICAM-4 vers de l'intégrine plaquettaire alphaIibbeta3
WO2014167071A1 (fr) * 2013-04-10 2014-10-16 Synapse B.V. Composés et méthodes d'inhibition de la liaison de l'icam-4 à l'intégrine αiibβ3 plaquettaire

Also Published As

Publication number Publication date
NZ513882A (en) 2001-09-28
JPH11511120A (ja) 1999-09-28
AU6332396A (en) 1996-12-30
CN1186439A (zh) 1998-07-01
WO1996040250A3 (fr) 1997-01-23
CA2223885A1 (fr) 1996-12-19
EP0835135A2 (fr) 1998-04-15

Similar Documents

Publication Publication Date Title
US5976532A (en) Method of antithrombotic therapy using anti-GPIIb/IIIa antibodies or fragments thereof, including c7E3
US20200002423A1 (en) Method of administering an antibody
US6663863B2 (en) Method of inhibiting stenosis and restenosis
US7504102B2 (en) Anti-αvβ3 humanized monoclonal antibodies
JP4590734B2 (ja) 抗血栓薬およびヒト化抗フォンビルブランド因子モノクローナル抗体
CA2288198A1 (fr) Modulation du retablissement vasculaire par inhibition de l'adhesion des leucocytes et de la fonction leucocytaire
US20090010934A1 (en) Cell lines, ligands and antibody fragments for use in pharmaceutical compositions for preventing and treating haemostasis disorders
WO1996040250A2 (fr) Immunoglobuline chimerique specifique des plaquettes et procedes d'utilisation
EP0725655B1 (fr) Utilisation des substances capable d'attacher au glycoproteine gpIIb/IIIa pour la prévention de sténosis et resténosis
AU2004203082B2 (en) Platelet-specific Chimeric Immunoglobulin and Methods of Use Therefor
AU5838899A (en) Platelet-specific chimeric immunoglobulin and methods of use therefor
US20040101527A1 (en) CD18-binding antibodies and use thereof for inhibition and alleviation of stenosis-related symptoms and disorders

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 96194312.2

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1996922452

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 311914

Country of ref document: NZ

ENP Entry into the national phase in:

Ref document number: 1997 502244

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase in:

Ref document number: 2223885

Country of ref document: CA

Ref document number: 2223885

Country of ref document: CA

Kind code of ref document: A

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1996922452

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996922452

Country of ref document: EP